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ABSTRACT OF THESIS

EFFECTS ON SEMEN QUALITY AND ON ESTABLISHMENT OF PERSISTENT
EQUINE ARTERITIS VIRUS (EAV) INFECTION IN STALLIONS FOLLOWING
EXPERIMENTAL CHALLENGE WITH THE KENTUCKY 84 (KY84) STRAIN

Equine arteritis virus (EAV) is the causal agent of equine viral arteritis (EVA), a disease
of equids. Following EAV infection, up to 70% of stallions may become carriers and
continuously shed the virus in their semen for varying time periods. The long-term carrier
stallion has an important role in the transmission and maintenance of EAV in horse
populations. Recently, it has been demonstrated a correlation between in vitro
susceptibility of CD3+ T lymphocytes to EAV infection and establishment of long-term
persistent infection among stallions following natural infections. In this study, we
investigated whether stallions with in vitro EAV susceptible CD3+ T lymphocytes are at
higher risk of becoming long-term carriers compared to those with the resistant
phenotype following experimental infection with the KY84 strain of EAV. Furthermore,
we investigated whether there is a significant effect of EAV infection on semen quality
during acute phase of the infection. The data suggested that the establishment of the
long-term carrier state seems to be associated with the in vitro CD3+ T lymphocyte
susceptible phenotypes and that reduced semen quality resulted from the combined effect
of fever and scrotal edema observed following EAV infection rather than the direct effect
of the virus.
Keywords: Equine arteritis virus, equine viral arteritis, persistent viral infection, carrier
stallions, CD3+ T lymphocyte susceptible/resistant phenotypes
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CHAPTER ONE
Literature review

I. THE VIRUS AND THE DISEASE

1.1. EQUINE ARTERITIS VIRUS
Arterivirus is a genus of virus belonging to the family Arteriviridae, which in
1996, was included within the order Nidovirales (Cavanagh, 1997; Snijder and
Meulenberg, 1998). Equine arteritis virus (EAV) is the prototype virus in the family
Arteriviridae (genus Arterivirus, order Nidovirales). The family Arteriviridae (genus
Arterivirus) also includes porcine reproductive and respiratory syndrome virus simian
hemorrhagic fever virus (SHFV) and mice lactate dehydrogenase-elevating virus (LDV)
(Cavanagh, 1997; Snijder and Meulenberg, 1998).
The EAV virion is an enveloped, spherical, 50-nm to 65-nm particle with an
isometric core that contains a single-stranded, positive-sense ribonucleic acid (RNA)
(Maess et al., 1970; van der Zeijst and Horzinek, 1975; den Boon et al., 1991; Wieringa
et al., 2004). The EAV genome is encapsidated by a nucleocapsid protein (N) of 14 kDa,
which forms an icosahedral core structure. A lipid-containing envelope with small
surface projections, which contains seven proteins (E, GP2, GP3, GP4, ORF5a protein,
GP5, and M), surrounds the nucleocapsid (Figure 1.1.1.) (Snijder and Meulenberg, 1998;
Firth et al., 2011).
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Figure 1.1.1. Schematic representation of equine arteritis virus (EAV) particle
(Balasuriya, 2012).

The EAV genome length varies between 12,704 to 12,731 bp among different
strains (den Boon et al., 1991; Cavanagh, 1997; Snijder and Meulenberg, 1998; Zhang,
Timoney, et al., 2010), which includes a 5’ leader sequence with 224 nucleotides, and ten
open reading frames (ORFs 1a, 1b, 2a, 2b, 3, 4, 5a, 5b, 6, and 7), and a poly (A) tail at the
3’end (Figure 1.1.2.) (den Boon et al., 1991; van Dinten et al., 1997; Snijder et al., 1999;
Snijder and Meulenberg, 2001; Firth et al., 2011).
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Figure 1.1.2. Schematic representation of the genomic organization of equine
arteritis virus (EAV) (Balasuriya, 2012).

ORFs 1a and 1b occupy about three fourths of the most 5’-proximal end of the
genome and encode two replicase polyproteins (pp1a and pp1ab). ORFs 1a and 1b are
overlapping and their expression involves ribosomal shifting (Vries et al., 1992). Pp1a
and pp1b have identical N-terminals, but due to the ribosomal frame shifting, the Cterminals are distinct (den Boon et al., 1991). These two precursor proteins are
extensively processed after translation into at least 13 non-structural proteins (nsp1-12,
including nsp7 α/β) by three virus-encoded proteases (nsp1, nsp2 and nsp4) (Snijder and
Meulenberg, 1998, 2001; Ziebuhr et al., 2000).
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The seven envelope proteins (E, GP2 [previously known as GS], GP3, GP4, GP5a,
GP5 [GL], and M) and the nucleocapsid protein [N] make up the structural proteins of the
EAV virion and are respectively encoded by ORFs 2a, 2b, 3, 4, 5a, 5b, 6 and 7 located at
the 3’-proximal quarter of the EAV genome (Vries et al., 1992; Snijder and Meulenberg,
1998; Snijder et al., 1999; Firth et al., 2011). These structural proteins are expressed
from a 3’-coterminal nested set of six subgenomic viral messenger RNAs (sgmRNA) and
not from the genomic RNA (de Vries et al., 1990). The 3’-end of the sgmRNAs of EAV
have the same 3’-end as genomic RNA, but the 5’-end is variable (Miller and Koev,
2000). Three of the minor envelope proteins (GP2, GP3, and GP4) in the EAV virion are
covalently associated and form a heterotrimer; whereas, the two major envelope proteins
(M and GP5) form a disulfide-linked heterodimer (de Vries et al., 1995; Wieringa et al.,
2004). It has been shown that the major GP5 and M proteins, and the N protein are
essential for virus particle formation, but not the E and the GP2, GP3, and GP4 minor
proteins (Wieringa and Vries, 2004). In contrast, all envelope proteins are essential for
the production of infectious progeny virus, and elimination of ORF5a by reverse genetics
resulted in defective progeny virus, with small plaque phenotype and significant reduced
virus titer (Wieringa et al., 2004). The amino terminal ectodomain of GP5 protein
contains the known major neutralization determinant of EAV (Balasuriya et al., 1993,
1997, 2000, 2004; Deregt et al., 1994; Chirnside, de Vries, et al., 1995; Glaser, de Vries,
and Dubovi, 1995). It has been demonstrated that heterodimerization of GP5 with M
proteins is critical for the post-translational modification (glycosylation) and
conformational maturation of neutralization determinants in the GP5 protein to form
EAV epitopes that induces neutralizing antibodies in mice, and horses (Balasuriya et al.,
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2004; Zhang, Timoney, Maclachlan, and Balasuriya, 2008). Although considerable
variation occurs in the sequence of the GP5 protein of field strains of the virus, there is
only one known serotype of EAV and all strains evaluated so far are neutralized by
polyclonal antiserum raised against the virulent Bucyrus strain of EAV (Timoney and
McCollum, 1993a; Balasuriya and MacLachlan, 2004). Even though there is only one
recognized serotype of the virus, not all strains are neutralized to the same degree by
antiserum raised against various strains of EAV (Balasuriya et al., 1997, 1998; Balasuriya
et al., 1999; Hedges et al., 1999; Zhang et al., 2010).
A number of studies have shown that different strains of EAV vary significantly
in their pathogenicity, with different clinical outcomes upon experimental inoculation of
horses (Balasuriya et al., 1999; McCollum and Timoney, 1999; Balasuriya et al., 2002;
Balasuriya et al., 2007).
EAV is inactivated immediately by common and lipid solvents (ether and
chloroform), disinfectants and detergents. It has been reported that tissue culture fluid
containing the experimentally adapted derived virulent Bucyrus strain of EAV survives
approximately 75 days at 40C, 2 to 3 days at 370C, and 20 to 30 minutes at 560C
(McCollum et al., 1961). The virus is stable at -700C for years without loss of infectivity
(Crawford and Henson, 1973). Lyophilized virus is highly stable at -200C and moderately
stable at 40C (Harry and McCollum, 1981).
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1.2. EQUINE VIRAL ARTERITIS
1.2.1. History
Equine viral arteritis (EVA) is an acute, contagious, respiratory and reproductive
disease of equids caused by EAV. EAV was first isolated from a lung of an aborted fetus
in 1953 following an extensive outbreak of respiratory disease and abortion in a
Standardbred breeding at Bucyrus, Ohio, U.S.A. (Doll et al., 1957b; Doll, Bryans, and
Knappenberger, 1957). Although descriptions of a disease in late 18th and early 19th
centuries was very likely EVA, this was referred as “infectious or epizootic cellulitis”
(Hodgins and Haskett, 1907), “influenza erysipelatosa,” “Pferdestaupe,” “Rotlaufseuche”
(Balasuriya and MacLachlan, 2007) “pinkeye” (Mohler, 1917) and “equine influenza”
(Huidekoper, 1923), EVA was characterized as a new disease only in the 1950s, after the
causal agent was isolated and the vascular lesions found on histological examination of
acutely infected cases was characterized (Doll et al., 1957a; Doll et al., 1957b; Doll,
Bryans, and Knappenberger, 1957). The virus obtained from the Ohio outbreak was
referred as the Bucyrus strain from which the prototype strain of EAV was isolated with
the American Type Culture Collection catalogue designation VR-796™ (American Type
Culture Collection, 1992). Outbreaks of EVA have been reported worldwide
(Switzerland, Austria, Poland, Italy, the United Kingdom, Spain, the Netherlands, Canada
and the U.S.A.) after the identification of the causal agent of the disease (Jaksch et al.,
1973; Clayton, 1987; Autorino et al., 1992; Nowotny, 1992; Weiis et al., 1994; Monreal
et al., 1995; Balasuriya, 2012). Several outbreaks of the disease took place in the U.S.A
since the outbreak reported in 1953, in Ohio. Major outbreaks have occurred during the
1900s in: Kentucky (1977 – Standardbred racetracks and 1984 – Thoroughbred breeding
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farms), Illinois (1993 – Thoroughbred racetracks) and Pennsylvania (1996 – a single
Warmblood breeding farm) (Balasuriya, 2012). The 1984 EVA Kentucky outbreak was
the first recorded in the Thoroughbred population in the U.S.A., and it generated
widespread interest and major concern to the equine industry. Epidemiological data
collected from that outbreak strongly suggested the occurrence of long-term persistence
of EAV in stallions and the importance of the carrier stallion in the dissemination and
perpetuation of the virus within the horse population (Timoney and McCollum, 1985).
There had been a number of recent outbreaks reported in Europe, North America and
South America. These include: (1) the 2006/2007 multi-state occurrence of EAV in the
U.S.A. affecting initially American Quarter Horses and subsequently spreading to horses
of 11 different breeds located in 9 different states (Timoney et al., 2008; Zhang et al.,
2010); (2) the extensive 2007 event in France that affected draft and saddle horses and
involved 8 mortality cases including 1 fetus, 5 young foals and 2 mature horses (Pronost
et al., 2010; Miszczak et al., 2012); and (3) the 2010 outbreak in Argentina affecting
mainly sport-horses with abortion rates reaching about 50% and 38 stallions becoming
seropositive for EAV (Committees Infectious Diseases of Horses, 2010).

1.2.2. Seroprevalence, distribution and transmission
Serologic surveys have shown that EAV infection is distributed worldwide and
have been reported in the horse populations in North and South America, Europe, Africa,
Asia, Australia and New Zeland (Jaksch et al., 1973; McCollum and Bryans, 1973;
Moraillon and Moraillon, 1978; de Boer et al., 1979; Huntington et al., 1990; Timoney
and McCollum, 1993b; Monreal et al., 1995; Huovilainen and Ek-Kommonen, 1998;
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Newton et al., 1999). Iceland and Japan are free of EAV infection (Balasuriya, 2012).
The seroprevalence of EAV infection varies not only between countries but also between
horse populations of different breeds and ages within the same country (McCollum and
Bryans, 1973). Studies have shown that there is a marked disparity in seroprevalence of
EAV infection between Standarbreds (78 to 84%) and Thoroughbreds (<5%) in the USA,
with the infection being considered endemic in the Standarbred horse population in this
country (McCollum and Bryans, 1973). A serologic survey done with 226 imported
horses from several countries to California have demonstrated that the prevalence of
EAV infection appears also to be high in European Warmbloods (Hullinger et al., 2001).
Antibodies against EAV have been found in: donkeys and mules in Brazil (Bello, 2006)
and South Africa (Paweska and Barnard, 1993; Paweska et al., 1995, 1997); and donkeys
in Italy (Ramina et al., 1999). In addition, experimental inoculation of donkeys with EAV
caused clinical disease, shedding of the virus in the semen of males and seroconversion to
EAV (McCollum et al., 1995; Paweska et al., 1995). EAV-specific neutralizing
antibodies were also detected in 12 of 51 (24%) zebras of the Burchell’s zebra population
in the Serengeti National Park, Tanzania (Borchers and Wiik, 2005), but not in 266 park
or captive zebras from 9 different countries such as South Africa, Kenya, Zimbabwe,
Botswana, Germany, Netherlands, Australia, Canada and the USA (Paweska et al., 1997).
Antibodies to EAV were also found in a herd of alpacas in Germany. A case of late
abortion in an alpaca from the same cohort was reported and genome fragments of EAV
could be detected in the fetal tissues by using reverse-transcription polymerase chain
reaction (RT-PCR) (Weber et al., 2006).
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Transmission of EAV occurs mainly by the respiratory (Doll, Bryans, and
Knappenberger, 1957; McCollum et al., 1971) and venereal routes (Timoney et al., 1986,
1987). Transmission via respiratory route requires direct contact between susceptible
horses and acutely infected animals or their contaminated body secretions as urine,
vaginal secretions, feces, aborted fetuses and their membranes and, masturbates of
stallions (Doll, Bryans, and Knappenberger, 1957; McCollum et al., 1971; Fukunaga et
al., 1981; McCollum and Timoney, 1984; Cole et al., 1986; Timoney and McCollum,
1993a; Guthrie et al., 2003). Although virus is shed in tissues and bodily fluids, the
amount and duration of the virus shed is greater into the respiratory tract and it varies
from around 7 to 14 days during acute infection (McCollum et al., 1971). Acutely or
chronic persistently infected stallions play a major role in the venereal transmission of
EAV to mares, during natural breeding and artificial insemination with fresh, cooled and
frozen semen (Timoney et al., 1986, 1987; Balasuriya et al., 1998; Balasuriya, Hedges, et
al., 1999). Persistently infected stallions shed virus only in semen and 85 to 100% of
mares bred to these long-term carrier stallions seroconvert to EAV within 28 days
(Timoney and McCollum, 1985, 1993a; Timoney et al., 1986, 1987). Other less common
modes of dissemination of EAV include vertical (transplacental) and indirect
transmission. Although rare, exposure of pregnant mares to EAV late in gestation can
result in transplacental transmission of the virus and congenital infection of the fetus
(Vaala et al., 1992). Indirect spread of EAV via contaminated fomites, such as shanks,
artificial vaginas, twitches, apparel or personnel, has been reported and it is thought to
play a minor role in the transmission of the virus (Collins et al., 1987; Timoney and
McCollum, 1993a; Glaser et al., 1996; Balasuriya et al., 1999). Other sources of EAV can
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be an infected teaser stallion or a nurse mare (Timoney, 1984; Timoney and McCollum,
1993a). Recently, it was demonstrated under experimental conditions, that embryo
transfer from a donor mare inseminated with EAV infective semen to naive recipient
mares, could represent a risk of EAV transmission (Broaddus et al., 2011).

1.2.3. Clinical Signs
The outcome of EAV infections in equids varies from subclinical to
influenza-like signs in adult horses, abortion in pregnant mares, interstitial pneumonia
and pneumoenteritis in young foals (Johnson et al., 1991; Vaala et al., 1992; Timoney
and McCollum, 1993a; Del Piero et al., 1997). Most infections with EAV results in an
unapparent illness, especially in mares bred to persistently infected stallions (Timoney et
al., 1987; Timoney and McCollum, 1993a). The development of clinical signs following
natural or experimental infection with EAV can vary considerable in severity among
individual horses and outbreaks (Timoney, 1984; Timoney and McCollum, 1993a). This
variability depends on a number of factors such as strain and dose of virus, route of
infection, age and physical condition of the animal at the time of exposure, environmental
conditions, and route of exposure (Timoney and McCollum, 1993a; McCollum and
Timoney, 1999; Balasuriya, 2012). Fever (up to 410C) develops after an incubation
period of 3-14 days (6-8 days in the case of venereal exposure) and may persist for 2-9
days. Typical signs of EAV may include pyrexia, depression, anorexia, leukopenia, nasal
and/or ocular discharge, conjunctivitis, rhinitis, urticarial, periorbital or supraorbital
edema, edema of the limbs, stiffness of gait, preputial and scrotal edema in stallions,
edema of the mammary glands and abortion in pregnant mares (Doll, Bryans, and

	
  

10	
  

Knappenberger, 1957; McCollum et al., 1971, 1995; Timoney and McCollum, 1993a;
Glaser et al., 1996). The most consistent clinical findings of EVA are fever and
leukopenia. Regardless of the severity of clinical signs, usually all naturally infected adult
horses recover spontaneously from infection. However, infected neonates and young
foals up to few months of age can die from a severe interstitial pneumonia or a rapidly
progressive pneumoenteric syndrome (Golnik et al., 1981; Carman et al., 1988; Vaala et
al., 1992). Abortion due to EAV is reported to occur between 3 and 10 months of
gestation and may occur late in the acute phase of the disease or early in the convalescent
phase of EVA, following natural or experimental infection of horses. Abortion rates
between 10 and 60% have been reported in the case of natural outbreaks of the disease
and are not necessarily preceded by clinical signs of EVA. Experimental infection with
the Kentucky 1984 strain of EAV lead to 71% abortion in pregnant mares (Doll, Bryans,
and Knappenberger, 1957; Cole et al., 1986; Johnson et al., 1991; Timoney and
McCollum, 1993a). However, it appears that different strains of EAV differ in their
virulence and abortigenic characteristics. Horses experimentally inoculated with virulent
strains of EAV (e.g., the VB, recombinant VB, and KY84) develop severe lymphopenia
with a high-titer viremia (McCollum and Timoney, 1984; MacLachlan et al., 1996;
Balasuriya et al., 2002; Balasuriya et al., 2007). In contrast, horses inoculated with the
attenuated modified live virus (MLV) strain or with other avirulent strains (e.g. 030H and
CA95) develop a mild lymphopenia with a low-titer viremia (Doll et al., 1968;
McCollum, 1969; Balasuriya et al., 1999; Patton et al., 1999).
Acutely infected stallions shed virus in their semen and it has been shown that
they experience a period of temporary subfertility believed to be the result of increased
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testicular temperature and scrotal edema, rather than a direct effect of the virus in the
semen. Reduction in the stallions libido during the acute phase of EAV infection have
been reported, in addition to the changes in the semen quality (decreased motility, sperm
concentration and percentage of morphologically normal spermatozoa) that persisted for
up to 6-7 weeks, (Neu et al., 1992). However, no long-term effects on stallions fertility
have been observed on long-term carrier stallions (Timoney and McCollum, 1993a).
Mares bred to persistently EAV infected stallions appear not to experience any short- or
long-term fertility problems (Raz et al., 2006).
Although mortality is very rare in horses following natural infection with field
strains of EAV, it has been reported that the highly virulent horse adapted Bucyrus strain
of EAV can cause up to 60% mortality in adult horses (MacLachlan et al., 1996).

1.2.4. Persistent infection and the carrier state in stallions
The establishment of persistent infection in the reproductive tract of the infected
stallions is a unique feature of EAV infection. The recognition of an asymptomatic carrier
stallion as a natural reservoir of EAV was first described in late 1800’s when it was noted
that a healthy stallion could infect mares with equine influenza or “pink-eye” at the time
of natural breeding but could not infect animals in close contact (Pottie, 1888; Reeks,
1902). It was known that those stallions could be infective for 2 or more years and mares
infected by them were able to transmit the disease to other contact animals via the
respiratory route (Pottie, 1888; Reeks, 1902). However, the EAV carrier state was better
elucidated only after the 1984 epizootic affecting the Thoroughbred horse population in
Central Kentucky, in which a high percentage of the naturally infected stallions were
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confirmed to shed EAV in their semen by isolation of the virus from the semen and/or
transmission of the disease to test-bred mares. Epidemiological data collected from that
outbreak strongly suggested the establishment of a long-term persistence of EAV in
stallions and the importance of the carrier stallion in the dissemination and perpetuation
of the virus within the horse population (Timoney and McCollum, 1985). In 1986,
Timoney et al. (Timoney et al., 1986) confirmed the chronic carrier state in 30-35% of
the stallions naturally infected during 1984. Subsequent studies confirmed the existence
of persistently infected stallions for many years, perhaps life long, with the frequency of
the carrier state varying somewhere between 30-60% in stallions exposed to EAV via the
respiratory route (Timoney et al., 1987; Neu and Timoney, 1988; Timoney and
McCollum, 1993a).
The virus persists in the male reproductive tract, specifically in the accessory
glands with highest titers being found in the ampulla of the vas deferens (Neu and
Timoney, 1988; Little et al., 1991), despite the presence of high titer neutralizing
antibodies in serum (Timoney et al., 1986; Timoney et al., 1987; Neu and Timoney,
1988; Little et al., 1991). Virus is not present in the nasopharyngeal secretions, blood,
urine, or other body secretions of long-term carrier stallions. Isolation of EAV from the
pre-ejaculatory fluid of persistently infected stallions was not successful and thus, virus is
believed to be associated with the sperm-rich fraction of the ejaculate. In addition,
assessment of the shedding status of a putative carrier stallion was best undertaken with
entire ejaculates rather than dismount samples. However, dismount samples are a feasible
alternative choice in the case when entire ejaculates cannot be obtained (Timoney,
McCollum, and Roberts, 1986; Timoney et al., 1987; Little et al., 1991). Stallions can
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become carriers and continuously shed the virus in their semen for varying time periods,
from weeks (convalescent or short-term carriers) to years (chronic or long-term carriers)
(Timoney et al., 1986; Timoney, McCollum, and Roberts, 1986; Timoney et al. 1987;
Neu and Timoney, 1988). Intermittent virus shedding or the presence of a latent period of
EAV has never been demonstrated. Persistently infected stallions can stop shedding virus
in their semen years following infection with EAV with no evidence of reversion to a
shedding state at a later date (Timoney and McCollum, 1993a). The mechanism of EAV
persistence in the reproductive tract of stallions is unclear, however it has been shown
that establishment and maintenance of infection is testosterone dependent (Little et al.,
1992; Holyoak et al., 1993; McCollum et al., 1994). Surgical castration of long-term
carrier stallions resulted in either viral clearance or significant reduction of virus
shedding in their semen. In contrast, castrated persistently infected stallions that received
supplementation of testosterone subcutaneously kept shedding virus in their semen for as
long as non-castrated carrier stallions (Little et al., 1992). It was suggested that high
levels of testosterone are necessary for maintenance of the virus in the reproductive tract
of stallions but not for viral replication and persistence of EAV for an intermediate period
of time (months). Prepubertal and peripubertal colts experimentally inoculated with EAV
remained infected in the reproductive tract for a considerable period of time, even though
testosterone levels in these animals are lower than in stallions. These findings have
confirmed that the virus can replicate in the male reproductive tract for an intermediate
period of time in the absence of circulating concentrations of testosterone equivalent to
those found in sexually mature stallions. However, long-term persistent infection does
not appear to occur in colts exposed to EAV before the onset of puberty (Holyoak et al.,
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1993). Similarly, persistence of EAV has never been reported in mares, gelding, or
fetuses (McCollum et al., 1994; Timoney and McCollum, 1993; Timoney et al., 1986;
Timoney and McCollum, 1987b). Thus, persistently infected stallions can be divided into
three groups based on the duration of virus excretion in semen: (1) the short-term or
convalescent carrier state (few weeks following clinical recovery); (2) the intermediate
carrier state (3 to 7 months); and, (3) the long-term carrier state (years to lifetime) (Little
et al., 1992; Holyoak et al., 1993; Timoney and McCollum, 1993a).
One of the explanations for long-term persistence of EAV infection in the
reproductive tract of mature stallions could be the immunosuppressive activity that
testosterone is believed to have. Several in vitro studies have suggested that testosterone
inhibits lymphocyte proliferation, cytokines production, and macrophage activity
(Muehlenbein and Bribiescas, 2005). In addition to the immunosuppressive activity,
testosterone plays an important role in the maintenance of susceptible host cell population
of the male reproductive tract (Amann, 2011a), which supports viral persistence, and it is
an important mechanism of viral immune system evasion (Alcami and Koszinowski,
2000). Another important function of testosterone in peripheral blood is to ensure normal
function of all accessory sex glands (Thompson et al., 1979), which in turn, contribute
most of the fluid to the ejaculate (seminal plasma). Seminal plasma contains
immunosuppressive factors, which are believed to protect sperm from immunological
damage and prevent sensitization of the female reproductive tract to sperm antigens
following coitus, which is fundamental to the process of reproduction itself. But this
benefit is not without risk; the local immune response to bacteria and viruses might be
inhibited and, therefore, accessory cells might be prevented from recognizing bacterial or
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viral antigens (James and Hargreave, 1984). However, EAV mostly persists in the
ampulla of the vas deferens, which is located distally to the other accessory glands of the
stallion. Thus, the immune suppressive factors of seminal plasma would have to come
from the fraction of seminal plasma produced by the ampulla to have an immune
suppressive effect on virus replication, which seems unlikely to happen. These could
possibly be EAV strategies to evade the immune system and establish persistent infection
in the reproductive tract of stallions.
Recently, other explanations for viral persistence in the reproductive tract of
stallions have been suggested in addition to viral testosterone dependence. It is assumed
that virus persists by continuously re-infecting susceptible tissues in the reproductive
tract together with constant evolution of antigenic variants of the virus (Balasuriya et al.,
1999; Hedges et al., 1999; Balasuriya, 2004). Until 2008, there was no information
available about host and viral factors involved in the establishment and maintenance of
EAV infection, other than testosterone. Thus, Zhang et al. developed an in vitro model
system in an attempt to elucidate the mechanism of EAV persistence. Reverse genetics
studies using an EAV infectious cDNA clone showed that amino acid changes in the
structural proteins of the virus (E, GP2, GP3, GP4, and GP5) were responsible for the
establishment of persistent infection in HeLa cells (Zhang et al., 2008). Previous studies,
in which EAV isolated from the semen of long-term carrier stallions was sequenced, have
shown that genetic variants emerge during the course of long-term persistent infection in
stallions (Hedges et al., 1999; Balasuriya, 2004).
Sequence analysis of strains isolated form the semen of EAV carrier stallions
have shown the emergence of novel genotypic and phenotypic variants (Balasuriya et al.,
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1998; Balasuriya, et al., 1999; Hedges et al., 1999; Patton et al., 1999; Balasuriya, 2004;
Zhang et al., 2010; Miszczak et al., 2012). EAV, as a RNA virus, mutates frequently and
therefore exists not as a single genotype, but rather, as a heterogeneous population of
related viral genomes known as quasispecies that facilitates its adaptability and survival
(Cavanagh, 1997; Domingo, 1997). It has been suggested that, perhaps, major outbreaks
of EVA are the result of the emergence and selection of specific variants of the virus
present in the semen of carrier stallions, however the mechanism of selection remains
unclear (Balasuriya et al., 1999). High rates of nonsynonymous amino acid changes were
observed in regions of the GP3 and GP5 structural proteins of EAV isolated from
infective semen (Hedges et al., 1999; Balasuriya, 2004) indicating that those proteins are
under constant selective pressure during the establishment and persistence of EAV
infection in the reproductive tract of carrier stallions (Balasuriya et al., 1997; Hedges et
al., 1999). Variation in the GP5 protein was found to have occurred in the specific V1
variable region critical for neutralization of the virus by some monoclonal antibodies and
polyclonal equine antisera, which correlates with the emergence of novel variants with
distinct neutralization phenotype during persistent infection (Balasuriya et al., 1997,
2004; Hedges et al., 1999; Balasuriya and MacLachlan, 2004). However, all variants that
arise during persistence of EAV infection are neutralized by polyclonal equine sera from
the same carrier stallion, therefore, immune evasion may not be entirely responsible for
the establishment and maintenance of the virus in the reproductive tract of carrier
stallions (Hedges et al., 1999; Balasuriya, 2004). In contrast, EAV that circulates during
outbreaks associated with horizontal and vertical transmission, generally, is relatively
genetic stable (Hedges et al., 1999; Balasuriya, 2004). Interestingly, the molecular
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epidemiologic and genetic characterization of the EAV isolates collected for an extended
period of time (9-10 months) during the multi-state occurrence of EVA in 2006-2007, in
the USA, showed a high mutation rate and genetic diversification of the strain involved in
this disease event, even though the principal mode of transmission of EAV in this
outbreak was horizontal and vertical. That event provided a unique opportunity to assess
the genomic stability of the virus during lateral and vertical transmission over an
extended period of time. Data from that study suggested that the EAV genome remains
genetically relatively stable over a short time period. However, genomic variability
tended to increase if horizontal and vertical transmission took place over a more extended
time period. In addition, it was the first time that a study was based on a great number of
stallions (n=8) and on the evaluation of the full-length genomic sequences of 18 EAV
isolates collected sequentially from those stallions. From the results, it was evident that
EAV evolved genetically during persistent infection, but the evolution rate varied
according to the individual stallion and the period of viral shedding of particular stallion.
The longer the shedding period, the more accumulated mutations were observed in the
virus genome.

1.2.5. Pathogenesis
Most of the information on the pathogenesis of EVA is derived from experimental
inoculation of horses but the exact mechanism of EVA pathogenesis remains to be
determined (Doll et al., 1957b; Estes and Cheville, 1970; McCollum et al., 1971; Prickett
et al., 1972; MacLachlan et al., 1996).
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EAV has been isolated from a variety of tissues and body fluids, such as, spleen,
liver, kidneys, bronchial and mesenteric lymph nodes, endothelium and mesothelium,
buffy coat, reproductive tract of colts and stallions, and semen, starting from 1 to 2 dpi
following experimental inoculation (Estes and Cheville, 1970; McCollum et al., 1971,
1994; Breese and McCollum, 1972; Neu and Timoney, 1988; Neu et al., 1992; Holyoak
et al., 1993; Del Piero, 2000).
Virus can be isolated from the nasopharynx, buffy coat, and serum or plasma for
varying period of times following intranasal exposure. The disappearance of virus from
serum coincides with the development of EAV-specific neutralizing antibodies, which
occurs approximately between 6 and 9 dpi (McCollum et al., 1971; Summers-Lawyer et
al., 2011; Balasuriya, 2012). Apart from its incidental recovery from the buffy coat and
its isolation from the reproductive tract of colts and stallions (Neu and Timoney, 1988;
McCollum et al., 1994), EAV is generally not detectable in most tissues after 28 days
following infection.
Following approximately 1 day post respiratory infection, EAV replicates in the
respiratory tract epithelium and pulmonary macrophages (McCollum et al., 1971;
MacLachlan et al., 1996; Del Piero, 2000; Balasuriya, 2012). After 2 days post-infection
(dpi), the virus proliferates and gains entry into the bronchial lymph nodes and is
disseminated to circulating monocytes and endothelial cells (McCollum et al., 1971; Del
Piero, 2000). Virus is then systemically distributed throughout the body (viremia)
(McCollum et al., 1971; MacLachlan et al., 1996; Del Piero, 2000; Balasuriya, 2012).
Endothelial cells and macrophages are the principal sites of virus replication, but EAV
also replicates in selected epithelia, mesothelium, and smooth muscle cells of the tunica
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media of smaller arteries, venules, and may also infect the myometrium (Coignoul and
Cheville, 1984; Johnson et al., 1991; Del Piero, 2000; Balasuriya and MacLachlan,
2004). A characteristic panvasculitis involving the small arteries and, to a lesser extent,
the small veins throughout the body, is observed. Initially the endothelial cells of the
intima are compromised and then the tunica media, followed by the adventitia (Doll et
al., 1957a). The clinical manifestations of EVA reflect the hemorrhage and edema that
occur around affected vessels caused by the increased vascular permeability and
leukocyte infiltration from the generation of chemotactic factors (Estes and Cheville,
1970). The vascular lesions of EVA are likely the result of the direct effect of viral
replication and virus-induced inflammatory cytokines on vascular endothelium, rather
than the result of immune-mediated injury (Moore et al., 2003; Balasuriya, 2012). In vitro
EAV infection of macrophages and endothelial cells demonstrated an increase in the
transcription of genes encoding proinflammatory mediators (Moore et al., 2003). This
study strongly suggested that cytokine mediators produced by endothelial cells and
machrophage have a central role in the pathogenesis of EVA.
Recently, it has been demonstrated that the clinical outcome of EVA infection is
determined by host genetic factors (Go, et al., 2012). Go et al. showed that clinical signs
and viremia burdens are greater in horses that have their CD3+ T lymphocytes resistant to
in vitro EAV infection compared to horses that have susceptible CD3+ T lymphocytes. In
addition, a significant difference between the two groups was found in terms of
proinflammatory and immunomodulatory cytokine mRNA expression.
The pathogenesis of EAV-induced abortion is controversial. Doll et al. concluded
that abortion is the result of infection of the fetus by the virus rather than from secondary
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influences such as, fever, toxemia, or debility of the mare, since it occurs during the early
convalescent period of the disease (Doll, Bryans, and Knappenberger, 1957). The aborted
fetuses contain higher concentration of virus than the dams, which suggests that viral
replication occurs in the fetus. Fetal stress activates the fetal-hypothalamic-pituitary axis
and may cause abortion (MacLachlan et al., 1996). However, other authors, based upon
light and electron microscopic studies of tissues from the genital tracts, placentae and
fetuses of mares experimentally infected with EAV, suggested that abortion may result
from a necrotic myometritis observed in the uterus of the EAV infected mares rather than
fetal infection with the virus (Coignoul and Cheville, 1984). Another possible
explanation for abortion caused by EAV infection is an impaired utero-placental blood
flow due to generalized vascular necrosis (Doll et al., 1957a) or due to mechanical
compression on blood vessels caused by edema in myometrium or from tissue distension
by loss of myometrium tonicity (Vaala et al., 1992). In addition, it has been suggested
that a decrease of progesterone production by the injured placenta and local release of
prostaglandins could also be one of the mechanisms involved in EAV infection abortion
(Coignoul and Cheville, 1984).
Fetuses aborted following natural or experimental infection with EAV frequently
do not show any gross or histopathological lesions (Doll et al., 1957b; Doll, Bryans, and
Knappenberger, 1957; Coignoul and Cheville, 1984; McCollum and Timoney, 1984).
Fetuses are usually partially autolyzed at the time of expulsion (Doll et al., 1957b; Doll,
Bryans, and Knappenberger, 1957). The placenta typically is grossly unremarkable and
expelled with the fetus, however placentitis characterized by vasculitis has been
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described during an outbreak in Thoroughbred horses that occurred in Oklahoma in 1987
(Johnson et al., 1991).

1.2.6. Immune response of horses to equine arteritis virus infection
The immune response to viral infection comprises innate and adaptive defenses.
The innate immune response (native or natural immunity) is the first line of defense of
the organism and acts very quickly, within minutes to hours after viral infection. It is
constantly present and thus, previous exposure to the virus is not required to activate this
mechanism. The innate defense has an important role in the detection of invading
pathogens and in limiting their spread; it also plays an important role in activation of the
adaptive immune response (Racaniello, 2009; MacLachlan and Dubovi, 2011).
In contrast, the adaptive immune response (acquired immunity) is the second line
of defense and is responsible for total clearance of pathogens. While the innate immunity
is activated immediately, the adaptive immunity takes longer to develop. A key feature of
the adaptive immune system is memory. Repeat infections by the same virus are met
immediately with a strong and specific response that usually effectively stops the
infection with less reliance on the innate system. Immunological memory confers longterm protection against associated disease. Adaptive immunity involves cellular and
antibody (humoral) effector mechanisms, mediated respectively by T- and Blymphocytes (Racaniello, 2009; MacLachlan and Dubovi, 2011).
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A. Innate immune response
The primary entry of EAV following natural infection of horses is either the
respiratory or reproductive tracts (Timoney and McCollum, 1993a). Thus, the initial
defense following EAV respiratory or venereal infection of horses is provided by the
innate immune system of the mucosa lining the respiratory and genital tracts, respectively
(Balasuriya and MacLachlan, 2004). The innate immune response of horses to EAV
infection is not well elucidated, and so, it is assumed to be similar to what occurs during
viral infection of other species (Balasuriya and MacLachlan, 2004; MacLachlan et al.,
2008).
In response to viral infection, virus-infected cells in the mucosa, infiltrating
macrophages, and natural killer (NK) cells, release various antiviral proinflammatory
cytokines such as interferons type I INF-β, type I INF-α, and type II INF-γ, respectively,
as well as tumor necrosis factor (TNF-α) and interleukins (such as IL-12). These
cytokines confer antiviral resistance (INF-α and β) and initiate the adaptive immune
response (INF-γ) (Balasuriya and MacLachlan, 2004; MacLachlan et al., 2008).
However, it has been observed that EAV (Go et al., 2012 unpublished data) and porcine
reproductive and respiratory syndrome virus tend to inhibit Type I Interferon production
(Wang and Christopher-Hennings, 2012).
The role of innate immunity in the protective response of horses to EAV infection
has not yet been elucidated. In a recent in vitro study it was shown that cytokine
mediators (IL-1b, IL-6, IL-8, and TNF-α) are produced by EAV infected equine cells,
such as endothelial (EC), alveolar machrophages, and blood-derived machrophages. This
study showed that those EAV-induced, machrophage-derived cytokines are capable of
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inducing E-selectin (recruitment of leukocytes to the site of injury) expression by equine
ECs, and thus, suggested that these cytokines contribute to the characteristic vascular
injury observed during severe EAV infection. The EAV virulent strains produced higher
amount of cytokines compared to the EAV avirulent strains (Moore et al., 2003).

B. Humoral immune response
The humoral immune response to EAV is characterized by the development of
complement-fixing (CF) and virus-specific neutralizing (VN) antibodies (Timoney and
McCollum, 1993a). Complement-fixing antibodies develop 1 to 2 weeks after EAV
infection of adult horses, peak after 2 to 3 weeks, and decline to disappear by 8 months.
Neutralizing antibodies are also detected within 1 to 2 weeks after exposure, however
peak at 2 to 4 months, and persist for years (Timoney and McCollum, 1993a; Balasuriya
and MacLachlan, 2004; Summers-Lawyer et al., 2011). Several studies on the mechanism
of EAV neutralization have shown that EAV neutralizing activity is complement
dependent (Radwan and Burger, 1973a, 1973b; Radwan et al., 1973; Fukunaga and
Imagawa, 1993). EAV neutralization is believed to occur in two steps: (1) irreversible
binding between EAV and specific antibody to produce an infectious virus-antibody
complex (sensitized virus), and (2) inactivation of this complex by either complement or
anti-IgG (Radwan and Burger, 1973a). It has been shown that a decrease in EAV
neutralizing activity of horse, hamster, guinea pig, and rabbit antisera following heat
inactivation could be restored after addition of fresh complement (Radwan and Burger,
1973b). In addition to these finding homologous complement was more efficient in the
neutralization of sensitized virus when compared with heterologous complement
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(Radwan et al., 1973). Later, other authors determined that the use of 10% guinea pig
complement in viral suspensions was optimal for enhancement of serum neutralization
antibody response in serum neutralization tests in the diagnosis of EVA (Fukunaga and
Imagawa, 1993). The same authors conclude that the requirement of complement for
efficient virus neutralization is dependent on the virulence of the strain. Complement
dependent EAV neutralizing activity is associated with the IgG fraction of the sera, but
not with the IgM fraction (Radwan and Burger, 1973b; Fukunaga and Imagawa, 1993).
A long-lived virus-neutralizing antibody response is induced following viral
infection or vaccination of horses with the modified live attenuated strains or inactivated
virus vaccines and is protective against clinical disease (Doll et al., 1957b; McCollum,
1970; Fukunaga et al., 1992; Timoney and McCollum, 1993a; Balasuriya and
MacLachlan, 2004), but not always against re-infection with the virus (McCollum, 1969).
Appearance of neutralizing antibodies in serum (6-9 days post infection) coincides with
the disappearance of virus from the circulation of infected horses (McCollum et al., 1971;
Balasuriya, 2012). However, in chronically infected stallions, the virus persists in the
reproductive tract despite the presence of high neutralizing antibody titers in their serum
(Neu and Timoney, 1988; Timoney et al., 1987, 1986).
Foals born to immune (seropositive) mares acquire EAV-specific antibodies
following ingestion of colostrum and are protected against clinical EVA following
intranasal inoculation with virulent EAV at 6 days of age. Neutralizing antibodies appear
in the blood serum of the newborn a few hours after passive transfer, peak at 1 week of
age, and the levels decrease gradually to extinction between 2 and 6 months of age
(McCollum, 1976; Hullinger et al., 1998). Virus neutralizing antibodies are not detected
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in foals’ sera prior to nursing, and thus, passive immunity is believed to not occur
through the placenta (McCollum, 1976). Foals that receive colostrum should be
vaccinated only after the maternal acquired antibodies disappear because these antibodies
in their serum are capable of neutralizing the vaccine virus (McCollum, 1976).
The humoral immune response to structural EAV protein is variable and depends
on the EAV strain the animals were infected with, the interval after infection when sera
are collected, the individual horses responses, and the serological assay used (Hedges et
al., 1998; MacLachlan et al., 1998; Nugent et al., 2000). The humoral immune response
to EAV is mainly directed to the major envelope proteins GP5, M, and to the N protein
(Chirnside, et al., 1995; Kheyar et al., 1997; Hedges et al., 1998; MacLachlan et al.,
1998). The conserved C-terminal domain of the M protein contains linear epitopes, which
are recognized by all EAV-specific horse anti-sera (Jeronimo and Archambault, 2002).
The M protein was the most consistently recognized by convalescent sera from EAVinfected horses, other than carrier stallions, while response to the N and GP5 protein was
variable (Hedges et al., 1998; MacLachlan et al., 1998). However, resistance to
reinfection is assumed to be mediated by neutralizing antibodies directed against the GP5
protein of the major envelope proteins of the virus (Balasuriya et al., 1993, 1995, 1999).
Studies on the characterization of EAV antigenicity have determined that
neutralization determinants of EAV are located on the GP5 (GL) protein (Balasuriya et
al., 1993, 1995; Deregt et al., 1994). Balasuriya et al. (1993, 1997, 2004) produced a
large panel of neutralizing murine monoclonal antibodies (Mabs) to EAV and all bound
to a GP5 major envelope glycoprotein indicating that it expresses the epitopes responsible
for the neutralization of EAV. The authors showed that while the Mabs recognized
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different epitopes, they are all located in the GP5 protein. The neutralizing domain within
the GP5 protein is located between aa residues 75 and 104 (Glaser, de Vries, and Dubovi,
1995). Balasuriya et al. (Balasuriya et al., 1997) characterized at least four potential
neutralization sites (site A [aa 49], site B [aa 61], site C [aa 67 to 90], and site D [aa 99 to
106]). With the exception of site A, these sites were all located in the V1 variable region
(aa 61-121) within the second half of the N-terminal hydrophilic ectodomain of the GP5
protein. Studies using Mabs and reverse genetics have shown that substitution of
individual amino acids within the GP5 ectodomain resulted in differences in
neutralization phenotype of the recombinant viruses, analogous to differences in the
neutralization phenotype of field strains of EAV and variants generated during persistent
infection of EAV carrier stallions (Balasuriya et al., 1997, 2004). It has been
demonstrated that heterodimerization of GP5 with M proteins is critical for the posttranslational

modification

(glycosylation)

and

conformational

maturation

of

neutralization determinants in the GP5 protein to form EAV epitopes that induce
neutralizing antibodies in mice, and horses (Balasuriya et al., 2004; Zhang et al, 2008).
Characterization of the humoral immune response to EAV has been mainly
focused on the structural proteins of the virus. Recently, Go et al. (2011) studied the
equine humoral immune response to the nonstructural proteins (nsp) of EAV. The nsp are
essential to EAV replication and are the first viral proteins to be synthesized in cells
infected with the virus (Go et al., 2011). Data from this study showed that the equine
humoral immune response to EAV nsps is directed against nsp2, nsp4, nsp5, and nsp12.
None of the horse sera recognized nsp1, nsp3, and nsp6 through nsp11. Sera from horses
vaccinated with the modified live virus (MLV) vaccine recognized the nsp2 and nsp12,
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but not the nsp4 and nsp5. Therefore, nsp2 and nsp12 were suggested as a possible target
for developing a serological diagnostic assay to differentiate seropositive vaccinated
horses from naturally infected horses.

C. Cell mediated immune response
Cell-mediated immunity (CMI) involves, rather than antibodies, the action of the
white blood immune cells (leukocytes) in response to an antigen; among these cells,
lymphocytes play a crucial role in mediating cellular immune response (MacLachlan and
Dubovi, 2011). The CMI response is well characterized in other arteriviruses such as
PRRSV, and lactate dehydrogenase elevating virus (LDV) (Bautista and Molitor, 1997;
Balasuriya and MacLachlan, 2004). However, little is known about CMI response to
EAV. EAV-specific cytotoxic T-lymphocytes (CTL) were described using peripheral
blood mononuclear cells (PBMCs) from convalescent ponies experimentally infected
with EAV. The cytotoxicity induced by EAV-stimulated PBMCs was virus-specific and
mediated by CD8+ T cells; EAV-specific CTL precursors persisted for at least 1 year
after infection in ponies (Castillo-Olivares, 2003). Other than this study, there are no
comprehensive studies that describe the CMI response to EAV.

1.2.7. Diagnosis of equine viral arteriris
Diagnosis of EVA cannot be based solely on the clinical signs of the disease since
a number of other diseases of the horse resemble equine viral arteritis (Timoney and
McCollum, 1993a). These include other respiratory tract viral infections such as equine
herpes virus (EHV-1 and EHV-4), equine influenza virus, equine infectious anemia,
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equine rhinitis A and B viruses, equine adenovirus and other conditions which include
toxicosis caused by hoary alyssum (Berteroa incana), and purpura hemorrhagica
(Timoney and McCollum, 1993a; Balasuriya, 2012). Other two differential diagnosis of
EVA are African Horse Sickness and Getah virus infection, which do not commonly
occur in the Unites States (Timoney and McCollum, 1993a).
In the case of abortion, differential diagnosis of EVA include EHV-1 and rarely,
EHV-4. However, abortion due to herpesvirus can frequently be distinguished from
abortion caused by EAV, due the fact that in herpes viral infection, the fetuses are
expelled fresh and characteristic gross lesions can frequently be observed; in contrast,
EAV-infected fetuses are usually autolysed and pathognomonic lesions are rarely
detected (Timoney and McCollum, 1993a; Balasuriya, 2012). Based on the difficulty of
diagnosing EVA clinically, laboratory diagnosis of the disease currently relies on the
combination of virus isolation and immunohistochemistry, viral nucleic or antigen
detection (molecular diagnostics), and demonstration of virus specific antibody response
(serologic) (OIE, 2004; Balasuriya, 2012).

A. Virus isolation and Immunohistochemistry
Virus isolation (VI) is the current test approved by the World Organization for
Animal Health (OIE) for the detection of EAV in clinical specimens and from the semen
of carrier stallions, and is the prescribed test for international trade (OIE, 2004).
Propagation of EAV in cell culture can be done using a variety of continuous cell lines,
such as baby hamster kidney (BHK-21), African green monkey kidney (Vero and BSC1), rhesus monkey kidney (LLC-MK2; ATCC CCL-7), equine dermal cells (NBL-6;
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CCL57), rabbit kidney (RK-13; ATCC CCL-37 and LLC-RK1), equine ovary cells (EO),
hamster lung (HmLu), canine hepatitis virus-transformed hamster tumor cells (HS and
HT-7), equine macrophages, and pulmonary equine endothelial cells (EEC) (Wilson et
al., 1962; Hyllseth, 1969; Breese and McCollum, 1970; Radwan and Burger, 1973b;
Konishi et al., 1975; Shinagawa et al., 1976; Glaser, de Vries, and Dubovi, 1995; Moore
et al., 2002, 2003). However, high passage RK-13 cells (passage 399-409; KY RK-13
cells) are more sensitive than the low passage RK-13 (passage 194-204) and other cells
lines for EAV infection and therefore, the best choice for primary isolation of virus from
clinical specimens (OIE, 2004). The cytopathic effect (CPE) and virus titer can vary
significantly among cell lines. The CPE in EAV infected cells is usually characterized by
rounding, vacuolation, increased optical density, refractivity and detachment from culture
vessels (McCollum et al., 1961; McCollum et al., 1962; Konishi et al., 1975).
The most appropriate specimens for virus isolation from live animals are
nasopharyngeal and conjuctival swabs, and citrated or EDTA blood samples for
separation of buffy coat cells (Timoney and McCollum, 1993a; OIE, 2004; Balasuriya,
2012). Heparin was shown to inhibit EAV in cell culture and so heparinized blood is not
suitable for virus isolation (Asagoe et al., 1997). In the case of carrier stallions, the gel
free sperm-rich fraction of the ejaculate, with which EAV is associated (Timoney et al.,
1987), is optimal for virus isolation (Timoney and McCollum, 1993a; OIE, 2004;
Balasuriya, 2012). To confirm EAV-induced abortion, placenta, fetal fluids, lung, spleen,
and lymphoid tissues should be collected for virus isolation (Timoney and McCollum,
1993a; OIE, 2004; Balasuriya, 2012). Organs and lymph nodes associated with the
alimentary and respiratory tracts should be collected for virus isolation in suspected cases
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of “pneumoenteric” forms of EVA in young foals (Timoney and McCollum, 1993a;
Balasuriya, 2012).
Immunoperoxidase histochemistry of skin biopsies is an auxiliary, reliable, and
rapid assay for the clinical diagnosis of EVA in horses, especially when a cutaneous
macropapular rash is evident or occasionally in skin biopsies (Lopez and Piero, 1996;
MacLachlan et al., 1996; Del Piero et al., 1997). The identity of the isolates of EAV
should be confirmed by RT-PCR, immunofluorescence or immunoperoxidase staining, or
by microneutralization assay with EAV-specific antiserum (polyclonal) or monoclonal
antibodies (OIE, 2004; Balasuriya, 2012).

B. Serological diagnostics
A variety of serological tests, including virus neutralization (VN), complement
fixation (CF), indirect fluorescent antibody, agar gel immunodiffusion, the enzymelinked immunosorbent assay (ELISA), and the fluorescent microsphere immunoassay
assay (MIA) have been used for the detection of antibodies to EAV (OIE, 2004).
The virus neutralization test (VNT) is considered the “gold standard” for
detection and determination of antibodies to EAV (Senne et al., 1985) and it is described
in the OIE manual (OIE, 2004). Currently, the VNT is the only standardized test
recognized by the OIE and it is the only validated test accepted for international trade.
For diagnosis of acute EAV infection by the VNT, acute and convalescent sera should be
collected at a 21- to 28-day interval, and a fourfold or greater increase in serum antibody
titer is a confirmatory of recent infection (OIE, 2004; Balasuriya, 2012). Long-term
carrier stallions usually have high serum neutralizing antibody titers despite the presence
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of virus in their semen (Timoney, McCollum, Roberts, et al., 1986; Timoney et al., 1987;
Neu and Timoney, 1988; Little et al., 1991). Although the VNT is very sensitive and
highly specific, it has several disadvantages: it is expensive, labor-intensive and timeconsuming to perform. In addition, the cytotoxicity caused by antibodies directed to the
RK-13 cells can be confounded with viral CPE and so can be hard to interpret (OIE,
2004). Furthermore, the VNT test cannot discriminate between the serum antibody
response of vaccinated from naturally infected horses (Balasuriya and MacLachlan,
2004).
In an attempt to overcome these disadvantages several enzyme-linked
immunoassays (ELISA) have been developed to detect antibodies to EAV using whole
virus, synthetic peptides, or recombinant viral proteins (GP5, M, N) expressed from
bacterial or baculovirus systems, as antigens (Chirnside, Francis, and Mumford, 1995;
Chirnside, Francis, de Vries, et al., 1995; Hedges et al., 1998; Kondo et al., 1998; Cho et
al., 2000; Nugent et al., 2000; Starik et al., 2001; Wagner et al., 2003; Duthie et al.,
2008). Recently, a MIA has been developed and shown to have several advantages over
traditional ELISAs: accuracy, high sensitivity and specificity, reproducibility, highthroughput sample analysis and multiplex capability (Go et al., 2008). None of the
existent ELISAs or described MIA offers equivalent specificity and sensitivity enough to
replace the current VNT (OIE, 2004). The CF test, although of lower specificity and
sensitivity than ELISA and VNT, can be used in the diagnosis of recent infection (OIE,
2004).
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C. Molecular diagnosis
Molecular diagnostics have several potential advantages over the current virus
isolation procedure approved by the OIE for the detection of EAV. They are often faster
and less expensive (Balasuriya et al., 2002). Several standard RT-PCR (Chimside and
Spaan, 1990; St-Laurent et al., 1994; Ramina et al., 1999; Westcott et al., 2003), RTnested PCR (RT-nPCR) (Gilbert et al., 1997) and real-time RT-PCR (rRT-PCR) assays
(Balasuriya et al., 2002; Lu et al., 2008; Miszczak et al., 2011) have been developed for
the detection of EAV nucleic acid in tissue culture fluid, nasal secretions and semen.
These assays target different genes (ORFs 1b, 3, 4, 5, 6, and 7) and have different
sensitivities and specificities. Gilbert et al. (1997) were very successful in increasing the
sensitivity and specificity of an RT-PCR based assay, when using a RT-nPCR that
incorporates two primer pairs specific for ORF1b. Miszczak et al. (Miszczak et al., 2011)
optimized a rRT-PCR assay developed by Balasuriya et al. (2002), which provided
sensitivity equal to or slightly higher than that of virus isolation for the detection of
equine arteritis virus in semen. Three different one-step real-time RT-PCR reagents in
combination with two different magnetic bead-based RNA extraction methods were used
to test 409 semen samples. This assay may be a faster, convenient and more economical
alternative to VI, for detection of EAV nucleic acid in TCF and equine semen. In
addition, the standardization of molecular diagnostics assays between laboratories may be
easier in comparison with the standardization of the traditional diagnostics methods due
to automation and use of commercial reagents kits that provide less variability to the
assay (Miszczak et al., 2011).
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1.2.8. Prevention and treatment to equine arteritis virus
As already discussed above, horses naturally or experimentally infected with
virulent or avirulent EAV strains develop a long-lasting immunity against clinical disease
(Doll et al., 1957b; McCollum, 1969; Fukunaga et al., 1992; Timoney and McCollum,
1993a; Balasuriya and MacLachlan, 2004). Therefore, vaccination is a logical and
practical strategy for the control of EVA (Timoney and McCollum, 1993a; MacLachlan
et al., 2008). Several studies were performed with the goal of developing a safe modified
live virus (MLV) vaccine using the Bucyrus strain of EAV (Doll et al, 1968; McCollum,
1969, 1981, 1986; Timoney et al., 1988). In 1961, EAV was found to replicate in primary
cell cultures of horse kidney (HK) (McCollum et al., 1961) and subsequently in other cell
cultures (McCollum et al., 1962; Wilson et al., 1962). It was noted that viral virulence
was reduced by continuous passage in cell culture but its immunogenicity was retained.
Multiple passages of the highly virulent horse-adapted Bucyrus strain of EAV was
performed in horse kidney (HK), rabbit kidney (RK) and equine dermal (ED) cells and
viral attenuation was obtained (Doll et al., 1968; McCollum, 1969, 1986). This attenuated
strain of virus did not show any reversion to virulence after five consecutive passages in
horses (McCollum, 1969). The commercial MLV vaccine, ARVAC® was developed by
further passage of the VB strain in cell culture (passage history HK-131, RK-111 and
ED-24), and like the strains of earlier passage history, also shown to provide protection
against the disease (Doll et al., 1968; McCollum, 1969, 1986; Timoney and McCollum,
1988; Fukunaka et al., 1982). The MLV vaccine induces the production of VN antibodies
within 5 to 8 days post-vaccination (Timoney and McCollum, 1988). A single dose of the
MLV vaccine was shown to stimulate only transient and low levels of VN antibodies and
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thus, additional doses were necessary to boost antibody titers to levels able to be
maintained for at least 9 to 12 months (Fukunaga et al., 1982; McKinnon et al., 1986;
Timoney and McCollum, 1988). The MLV vaccine, ARVAC® is currently in use in
North America, while the inactivated adjuvant virus vaccine, ARTERVAC®, is approved
for use in certain countries in Europe (Balasuriya and MacLachlan, 2004; MacLachlan et
al., 2008). The adjuvant-containing, inactivated EAV vaccine is also administered
intramuscularly, and a booster immunization is recommended after 3 to 4 weeks and
annually thereafter. This vaccine induces the production of high neutralizing antibody
titers against EAV but its role in preventing persistent infection is less characterized than
that of the MLV vaccine (MacLachlan et al., 2008).
The MLV vaccine have shown to be safe for use in mares and to provide
protection against clinical signs of the disease, however, a transient mild fever response
and a mild and transient lymphopenia were observed in a small number of animals (Doll
et al., 1968; McCollum, 1969, 1986; Timoney et al., 1988). The MLV vaccine virus had
been isolated from the nasopharynx, usually for up to approximately 7 days from a few of
the vaccinated animals (Harry and McCollum, 1981; Fukunaga et al., 1982). Vaccinated
mares inseminated with EAV-infective semen did not develop clinical disease, but virus
was isolated for short period of times from the nasopharynx of these mares. Furthermore,
a seronegative contact became infected in the same study (McCollum et al., 1988).
Experimental vaccination studies have been also performed in pregnant mares (Doll et
al., 1968; McCollum, 1969, 1981; Broaddus, Balasuriya, White, et al., 2011) and stallions
(McKinnon et al., 1986; Timoney and McCollum, 1988), to ensure the safety of the
vaccine for these categories of animals. Similarly to mares, the use of the MLV was
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proved to be safe in stallions and protective against clinical signs of the disease, with the
only clinical response observed being a mild fever of short duration and a slight
leukopenia in some animals (Timoney and McCollum, 1988). In this study, horizontal
transmission of vaccine virus from vaccinated to susceptible in-contact stallions was not
demonstrated and in view of the very low titer of virus isolated from the nasopharyngeal
secretions, was considered unlikely to occur. The vaccinated stallions did not shed virus
in their semen or urine following vaccination with the MLV. In 2011, a study was
undertaken to re-evaluate safety aspects of the commercial MLV vaccine against equine
viral arteritis (ARVAC®) in stallions. Ten EAV seronegative stallions were vaccinated
with one single dose of the vaccine and 1 stallion shed virus in the semen, on days 4 and
6 post-vaccination. Thus, first-time vaccinated stallions should not have their semen
eligible for use for a minimum of 14 days to avoid the potential risk of virus transmission
or having vaccine virus detected in semen frozen from a recently vaccinated stallion
(Summers-Lawyer et al., 2011).	
  Safety of the MLV was not proved for pregnant mares,
especially in the last 2 months of pregnancy due the risk of abortion and because fetal
infections with the MLV after vaccination of the pregnant mares have been documented
(McCollum, 1969; Broaddus et al., 2011). Foals from immune dams will passively
acquired antibodies against EAV from the colostrum and so, should be vaccinated after 6
months of age; however, vaccination can be done earlier than 6 months of age in the case
of foals from non-immune dams or in high-risk situations (McCollum, 1976; Hullinger et
al., 1998). Vaccination of pre-pubertal colts is central to control the spread of EAV
infection, since vaccinated colts are resistant to the development of the persistently
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infected carrier stallion after exposure to EAV (Timoney and McCollum, 1988;
Balasuriya and MacLachlan, 2004).
Recently, a cDNA clone of the current MLV vaccine was generated. This
infectious cDNA clone is identical to the wild type virus with the exception of a unique
nucleotide mutation in ORF7 to distinguish recombinant vaccine virus from laboratory
and field strains of EAV (Zhang et al., 2012). The safety and efficacy of this vaccine was
evaluated following intranasally inoculation of the horses with the heterologous KY84
strain of EAV. The horses vaccinated with the recombinant MLV (rMLV) developed
high neutralizing antibody titers against EAV similarly to studies with the MLV vaccine
(Timoney et al., 1988; Summers-Lawyer et al., 2011), the animals shed reduced viral
titers for a short period of time in nasal secretions and in the PBMCs within the first week
of immunization. However, the level of protection provided by the rMLV vaccine did not
completely fully protect the horses from developing clinical signs of EVA, even though
these were of less severity. A formalin-inactivated virus vaccine without adjuvant was
also shown to induce high titers of VN antibodies after repeated doses (Fukunaga et al,
1990, 1992).
Current serological tests cannot discriminate between naturally infected and
vaccinated horses. Therefore, an effort to develop vaccines that make such discrimination
and also that lack replication of the virus in the bodily fluids has been attempted.
Examples include a GP5-specific oligopeptide and a bacterial fusion protein, both
containing a key neutralizing domain of GP5 protein; a Venezuelan equine encephalitis
virus replicon particle-based vaccine that co-expresses GP5 and M protein; a live marker
vaccine that lack the major neutralization domain in GP5; and, a DNA vaccine expressing
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ORF2b, -5, and -7 (Chirnside et al., 1995; Balasuriya et al., 2002; Castillo-Olivares et al.,
2003; MacLachlan et al., 2008). The rMLV vaccine mentioned above, for instance, also
has the advantage of providing a means of serologically differentiating EAV naturally
infected from vaccinated animals.
As with other viral disease, there is no specific treatment for horses infected with
EAV. There is currently no effective treatment to permanently eliminate virus from the
semen of carrier stallions, other than castration. Suppression or inactivation of GnRH is
responsible for decreasing the production and release of pituitary gonadotropins (LH and
FSH) and consequently reduces the release of steroids, including testosterone. EAV is
believed to be testosterone dependent (Little et al., 1992), and thus, some authors were
able to temporarily remove the virus from the semen of persistently infected stallions
with the use of a GnRH antagonist (Fortier et al., 2002) and a GnRH vaccine (Improvac®
or Equity®, Pfizer Animal Health, Australia) (Burger et al., 2006). However, the
treatment had the disadvantage of causing a transient decrease of circulating testosterone
concentrations and quality of semen produced. Miszczak et al. (2012) also evaluated the
efficacy of the Equity® anti-GnRH vaccine in persistently infected stallions by
investigating clearance of the virus, systemic testosterone levels, and subsequent recover
of fertility. This study was the first to use a considerable number of stallions (n=16) and
to demonstrate the correlation between plasma testosterone and EAV viral load in semen.
Plasma testosterone levels decreased during the first two months after vaccination and
was followed by a decrease in virus load until 7-8 months and EAV clearance. Most of
stallions cleared virus from semen between 3 and 10 months after treatment, and after 22
months EAV clearance was observed in all stallions. However, decreases in libido and

	
  

38	
  

semen quality were reported after GnRH vaccination and more research in this area needs
to be performed.
Potential antivirals against EAV, such as the phosphorodiamidate morpholino
oligomer (PMO) have been tested in vitro (van den Born et al., 2005; Zhang et al., 2010).
PMOs are single-stranded DNA analogues, usually 20-25 bases in length, water-soluble
and nuclease-resistant that can base pair with a complementary RNA target sequence and
form a steric blockade to interfere with gene expression, particularly with translation of
the genome of EAV (Summerton, 1999). Peptide-conjugated PMO (PPMO) has been
shown to be delivered more efficiently into cells and thus it was used for target of the 5’
untranslated region (UTR) of the EAV genome (van den Born et al., 2005). Treatment
with an antisense PPMO targeting the EAV 5’-terminus eliminated the virus from
persistently infected HeLa cells (Zhang et al., 2010). Furthermore, horse cells transfected
with small interfering RNA (siRNAs) targeting the ORF1ab prior to infection with EAV
drastically reduced virus titers in cell culture (Heinrich et al., 2009).
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II. THE STALLION REPRODUCTION

1.3. ANATOMY AND PHYSIOLOGY OF THE REPRODUCTIVE TRACT
The reproductive system of the stallion encompasses the scrotum, testes, spermatic
cord, excurrent duct system (efferent ducts, epididymides and deferent ducts), accessory
sex glands, urethra and penis (Senger, 2003). The anatomical development and
maturation of these tissues are essential for normal function of the reproductive tract and
attainment of reproductive capability is dependent on each (Little and Holyoak, 1992).

Scrotum
The scrotum contains the two testes, epididymides, spermatic cords, and cremaster
muscles. The scrotum plays a role in thermoregulation, support and protection of the
testes (Little and Holyoak, 1992). It is a pouch of skin composed of two scrotal sacs
located outside the body cavity into which the testes descend. The sacs lie on each side of
the penis. The scrotum wall consists of 4 layers (Figure 1.3.1.), from the outermost to the
innermost, they are: (1) skin: contains a large number of sweat glands and thermo
sensitive nerves required for maintenance of adequate temperature; (2) tunica dartos:
composed of smooth muscles fibers with connective tissue in between. It contracts,
raising (during cold temperatures) or lowering the testis (during hot months), in response
to changes in scrotal skin temperature. Development and maintenance of contractility of
the tunica dartos is under androgen control; (3) loose connective tissue or scrotal fascia:
allows for mobility of the testis vertically or horizontally, but normally prevents an 1800
rotation, and; (4) parietal vaginal tunic (Senger, 2003; Amann, 2011b). This innermost
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layer is closely apposed to the visceral vaginal tunic of the testis, but separated by a space
termed the vaginal cavity. A thin layer of fluid lines the vaginal cavity to permit the testis
to slide smoothly within the scrotum (Little and Holyoak, 1992).

Figure 1.3.1. Schematic illustration of the scrotal layers and the tubular pathway of
the typical mammalian testis (Senger, 2003).

Testes
The testis is the male gonad and its primary functions are the production and
secretion of spermatozoa and testosterone, the predominant male sex hormone. In
addition, the testis produces inhibin, estrogens and a variety of proteins believed to be
important to sperm function (Amann, 2011a). The testes have their long axis almost
horizontal to the body, but when retracted (during cold temperatures) they assume a more
vertical position, so the cauda of the epididymidis becomes ventrally rather than caudally
located (Senger, 2003). Two connective tissue layers cover the testes: the tunica
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albuginea and the visceral vaginal tunic, which together form what is called the testicular
capsule. Supporting strands of connective tissue extends from the tunica albuginea
closely associating the tunica with the testis parenchyma and dividing the testis into
lobules (Figure 1.3.1.) (Senger, 2003; Chenier, 2007).
A cross section of the testis reveals the parenchyma, which consists of the
seminiferous tubules (where spermatogenesis takes place) and an interstitial tissue made
of Leydig cells that produce testosterone, and also of blood vessels, connective tissue,
lymphatics and nerves (Senger, 2003).

i. Semineferous tubules and Sertolli cells
The seminiferous tubules are lined up by an epithelium that consists of developing
germ cells (spermatogonia, spermatocytes and spermatids) and the somatic Sertolli cells.
They are limited by a lamina propria made up of fibroblast, myoid somatic cells and
laminin. The myoid cells are capable of rhythm contractions allowing for movement of
spermatozoa and fluid from the seminiferous tubules towards the epididymis. The ends of
the seminiferous tubules join to the rete tubules, which are housed by the mediastinum
(the central connective core of the testis) (Figure 1.3.1.). The rete tubules terminate when
they fuse with one of the efferent ducts that leads to the epididymal duct (Amann,
2011b). Although seminiferous tubules diameter, length and volume increase with age
(Johnson and Neaves, 1981), the proportion of the testis they occupy (about 70%) is
constant across the years (Johnson and Varner, 1991; Little and Holyoak, 1992).
Sertolli cells are the somatic component of the seminiferous tubules and their role
in spermatogenesis is not well elucidated (Johnson et al., 1997). The probable functions
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of the Sertolli cells are: (1) to provide structural support to the developing germ cells and
nutrients for their growth; (2) movement of developing germinal cells within the
seminiferous epithelium; (3) release of mature spermatids in a process called spermiation;
(4) removal of the waste by phagocytizing degenerating germ cells and residual bodies at
the end of spermiation; (5) cell-to-cell communication with the developing germ cells,
the myoid cell layer, and Leydig cells; (6) secretion of fluids, proteins and hormones, that
have a role in spermatogenesis as well in the transport of the spermatozoa through the
seminiferous tubules to the rete testis; and, (7) formation of the blood-testis barrier
(Johnson et al., 2008). Adjacent Sertolli cells are tightly attached by junctional
complexes, which form the major component of the blood-testis barrier and separate the
seminal epithelium into two functional compartments: basal (houses spermatogonia and
early primary spermatocytes) and adluminal (houses primary and secondary
spermatocytes and spermatids) (Amann, 2011a) (Figure 1.3.2.). The blood-testis barrier
prevents cells from the immune system to gain access to the adluminal compartment and
destroy developing germ cells. Given that, spermatocytes and spermatids, which first
appear at puberty and not prior to the development of the immune system, are protected
and will not be recognized by the immune system as foreign cells. The immune system
barrier continues within the epididymal ducts that transport and store spermatozoa
(Johnson et al., 2008).
Some of the hormones produced by Sertolli cells are: androgen binding protein
(ABP), transferrin, inhibin, anti-Mullerian hormone, activins and estradiol. The function
of Sertolli cells is dependent on follicle-stimulating hormone (FSH) and testosterone
(Amann, 2011a).
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The young animal has a low number of Sertolli cells, which increases with age
and stabilizes during sexual maturation until senescence, declining with advanced age
(13-20 years old) (Johnson et al., 1997). The number of Sertoli cells in adult stallions
varies according to the season of the year, being higher during the breeding season than
in the non-breeding season (Johnson and Nguyen, 1986; Johnson and Varner, 1991).
Even though stallions are seasonal breeders, they can produce spermatozoa through out
the year. However, maximum testicular development and function occurs, in the Northern
Hemisphere, during May, June and July (breeding season). The number of Sertolli cells
in the testis is important to determine the production of spermatozoa. Higher the number
of Sertolli cells, more spermatozoa the testis can produce (Johnson and Neaves, 1981;
Johnson and Varner, 1991). During the non-breeding season stallions testis contain 31%
fewer Sertolli cells and produce 40-50% fewer spermatozoa (Amann, 2011b). There is a
positive correlation between the number of Sertolli cells and number of germ cells, and
consequently daily spermatozoa production per testis (Johnson and Carter, 1994).
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Figure 1.3.2. A section of the stallions seminiferous tubule showing the relationship
of the germ cells to the adjacent Sertoli cells (Equine Reproduction, 2nd edition).

ii. Interstitial tissue of the testis – Leydig cells
Leydig cells are the most abundant component of the interstitial tissue. The primary
role of Leydig cells is supporting spermatogenesis by the production and secretion of
testosterone (Johnson et al., 1997). Leydig cells also produce other steroids hormones as,
progesterone and estradiol, which aid in regulating function of the seminiferous
epithelium, the hypothalamic-hypophiseal axis, and the accessory sex glands (Amann,
2011a). Equine Leydig cells have a considerable amount of smooth endoplasmic
reticulum (SER) where pregnenolone is converted into testosterone (Johnson et al.,
1997).
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As a stallion matures, the total number and volume of Leydig cells per gram of
parenchyma as well the individual size of those cells increase. Leydig cells augment in
number over the years of a stallion’s life and the ratio of Leydig cells to seminiferous
tubules increases from 1:12 (2-3 years old stallions) to 1:4 (13-20 years old stallions).
With increasing of age, postpubertal Leydig cells are replaced by adult Leydig cells,
which are believed to produce more testosterone (Johnson and Neaves, 1981).
The number of Leydig cells per testis also is influenced by the season of the year
and a greater amount of these cells are found in the testis of a stallion in the breeding
season compared to the non-breeding season. During the non-breeding season, total
number of Leydig cells is decreased (about 35%) which explains the seasonal variation of
testosterone. Size of individual Leydig cells, though, appears to be constant through out
the year without suffering any variation of the season (Thompson, 1986). The seasonal
differences in Leydig cell smooth endoplasmic reticulum (SER) volume per testis was
correlated to seasonal changes in Leydig cell number, and the increase in intracellular
testosterone content during the breeding season was correlated to seasonal changes in
Leydig cell number and volume of SER per testis (Johnson and Thompson, 1987).
Although testosterone is the steroid of greatest physiological importance, Leydig
cells produce greater amounts of estradiol than testosterone (Amann, 2011a).
Leydig cells have luteinizing hormone (LH) receptors and increase production of
testosterone in response to LH as well to human chorionic gonadotropin (hCG)
stimulation.
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Spermatic cord
The spermatic cord extends from the inguinal ring (passageway from the body
cavity into the scrotum) to the dorsal pole of the testis. It suspends the testis in the
scrotum (Little and Holyoak, 1992). The spermatic cord houses the testicular vasculature,
lymphatics and nerves, as well as the duct deferens, the testicular artery and veins
(Amann, 2011b). The testicular veins form an elaborated network called pampiniform
plexus. The pampiniform plexus surrounds the highly convoluted testicular artery
eventually forming a single vein, and serves as a countercurrent heat exchange system.
Heat is transferred from the warm (390C) arterial blood from the body to the cooler
(330C) venous blood leaving the surface of the testis. This venous blood has been cooled
by heat loops from the testicular veins through the skin of the scrotum. Disruption or
modification of the cooling system can compromises or completely suppress
spermatogenesis (Senger, 2003).
The cremaster is a striated muscle located on the lateral to the spermatic cord and
helps in testicular support and control of testicular temperature raising or lowering the
testis for short period of times (Amann, 2011b).

Thermoregulation of testicular temperature
Maintenance of low testicular temperature (3 to 50C below than normal core body
temperature), in most mammals, is necessary in order for spermatogenesis to occur
(Setchell, 1998; Brito, 2007; Hansen, 2009). When testicular temperature is elevated due
to conditions such as fever, testicular trauma, inflammation, edema and others, the
thermoregulatory mechanism necessary to cool the testis and allow for normal
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spermatogenesis is disrupted (Johnson et al., 1997). Metabolism and oxygen demand
increase at a greater rate than blood flow goes from the testicular artery to the testes, and
testicular hypoxia occurs with consequent detrimental effects on sperm production and
quality (Setchell, 1998; Brito, 2007). Thermal regulation of the testis and epididymis
depends on the combined action of the scrotum (sweat glands, thermosensitive nerves
and tunica dartos muscle), pampiniform plexus, and the external cremaster muscle (Little
and Holyoak, 1992).
Elevated temperature of the testis to body temperature or higher, for as little as 2
hours, can affect and cause the death of germinal developing cells within the
semineferous tubules (Freidman et al., 1991), specially pachytene primary spermatocytes,
but also B-spermatogonia and spherical spermatids (Setchell, 1998; Brito, 2007).
Previous studies assessing the effects of increased testicular temperature in different
species such as, mice (Pérez-Crespo et al., 2008), rams (Rasooli et al., 2010), boars
(Wettemann et al., 1979), bulls (Karabinus et al., 1997) and stallions (Freidman et al.,
1991; Love and Kenney, 1999) have shown that transient, as well as, chronic exposure of
the testis to elevated temperatures can disrupt spermatogenesis.
In stallions, scrotal insulation for 24 and 48 hours resulted in a transitory
decrease in the number and quality of spermatozoa in the ejaculate, mostly between 10
and 40 days after temperature increase, and a recovery of seminal characteristics was
observed between 50 and 75 days after cessation of elevated testicular temperature
(Freidman et al., 1991). Prolonged exposure of the testis to elevated temperatures has
been shown to affect quality and functionality of spermatozoa within the epididymis in
some species, but has not been tested in stallions (Amann, 2011b).
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Excurrent duct system
The excurrent duct system allows for final maturation, storage and delivery of
spermatozoa to the pelvic urethra. It consists of the epididymis, efferent and deferent
ducts (Senger, 2003).

i. Epididymis
The epididymis is responsible for controlling the fertility acquisition of
spermatozoa (maturation) and also their exit from the male reproductive tract (Little and
Holyoak, 1992). The epididymis is divided into three anatomical regions: the caput
(head), corpus (body) and, cauda (tail) (Burns, 2007). Exposition of the epididymis to
testosterone, especially the caput and corpus, is essential for secretion of certain proteins
by the epididymal epithelium (Amann, 2011b).
Within the caput of the epididymis, efferent ducts converge into a single duct, the
epididymal duct. The function of the efferent ducts is to convey new spermatozoa and
rete fluid to the epididymal duct. Peristaltic contractions of a smooth muscular layer
surrounding the epididymal duct are responsible for spermatozoa movement along its
course. The duct continues through the caput, corpus and cauda epididymidis and is
continuous with the deferent duct (Senger, 2003). In the stallion, spermatozoa are
retained in the caput for approximately one day, where the rete fluid is reabsorbed and
replaced by secretions of the epididymal epithelium. Because of this reabsorption of
fluid, spermatozoa is much more concentrated in the tail than in the head of the
epididymis. Time required for spermatozoa to travel from the caput to the corpus of the
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epididymis is not altered by the frequency of the ejaculation, and averages about 4.1 days
(Little and Holyoak, 1992; Amann, 2011a).
Motility and fertility of spermatozoa begin to be evident as spermatozoa move
into the corpus where reside for approximately two days. Stallion spermatozoa are stored
in the cauda of the epididymis from 7-10 days where, eventually, reach full motility and
fertility, and can maintain the ability to fertilize an oocyte for several weeks (Little and
Holyoak, 1992). Spermatozoa stored in the cauda epididymis are transported by smooth
muscle contractions of the duct deferens to the ampulla, which leads to the pelvic urethra
(Senger, 2003). Spermatozoa entering the caput have a proximal cytoplasmic droplet
located near the base of its head. As the spermatozoa move along the epididymis this
droplet is translocated down their tail and it is lost in the distal tail or during ejaculation.
Retention of the droplet indicates faulty epididymal maturation (Varner and Johnson,
2011).
Spermatozoa are produced continuously regarding of ejaculation frequency
(Senger, 2003).

ii. Deferent ducts
The deferent duct is a continuation of the epididymal duct. It extends from the
cauda of the epididymis through the spermatic cord to the pelvic urethra. Because of its
thick smooth muscular wall the proximal deferent duct can be palpated through the
scrotal skin. As it approaches the pelvic urethra it widens into a structure called ampulla.
The ampulla is an enlargement of the deferens ducts that opens directly into the pelvic
urethra. The ampullar region is enlarged due to the thick wall associated with the
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presence of crypts and glands, and also presents a slightly increase of its luminal diameter
compared with the deferent ducts. The ampulla is considered by some authors to be an
accessory sex gland (Amann, 2011b).

Accesory sex glands
The accessory sex glands include the vesicular glands, prostate, and bulbourethral
glands (Amann, 2011b). The vesicular gland produces the gel portion of the ejaculate
whereas the bulbourethral glands produce the pre-ejaculatory fluid (Little and Holyoak,
1992). The secretion of prostate gland is thin and watery and it probably helps cleanse the
urethra during ejaculation and constitutes a major portion of seminal plasma, especially if
a second ejaculation occurs 1-3 hours after the first (Amann, 2011b).
Secretions from the accessory glands (as well as some from the ampulla of the vas
deferens) provide fluid for spermatozoa transport and constitute the seminal plasma, the
non-cellular part of semen. Additionally, these secretions provide nutrition and buffers to
alleviate hostile acidic conditions found in the female reproductive tract (Senger, 2003).
The sex glands products are secreted into the lumen of the pelvic urethra. Seminal plasma
is needed for delivery of the sperm (Amann, 2011a). It has an important role in the
modulation of breeding-induced endometritis through suppressive effects on complement
activation, polymorphonuclear leukocytes (PMNL) chemotaxis, and phagocytosis
(Troedsson et al., 2000). Fractionation of seminal plasma proteins suggested that some
proteins have a protective effect on viable spermatozoa, whereas others promote
phagocytosis and binding of dead spermatozoa and PMNL (Troedsson et al., 2005).
Recently, it was reported for the first time in the horse, that a seminal plasma protein,
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CRISP3 suppress PMNL/sperm binding in a dose-dependent manner (Doty et al., 2011).
The accessory sex glands, as well the ampulla, are dependent on testosterone in
peripheral blood for full development and maintenance of their structure and function
(Amann, 2011a).

Urethra
The urethra is a long tube that serves as an excretory canal for urine and semen
and that extends from the bladder to the free end of the penis. Its pelvic region is overlaid
by a thick, striated muscle that contracts vigorously during ejaculation. An erectile tissue
called corpus cavernous surrounds the penile urethra. The urethra terminates in a free
extension: the urethral process (Little and Holyoak, 1992).

Penis
The penis is the male copulatory organ. The stallion penis contains a large amount
of erectile tissue (corpus carvenosus) enclosed in a connective capsule, the tunica
albuginea. In addition, it contains a small amount of an erectile tissue surrounding the
urethra, the corpus spongiosum, which is not enclosed by the tunica albuginea. Thus, the
stallions’ penis is muculocarvenosus, and upon sexual stimulation the spongy tissue is
filled with blood increasing both the length and diameter of the penis. On the distal end
of the penis is the bell-shaped glans (Amann, 2011b). The glans region is highly
innervated and is responsible for inducing the ejaculatory process, which happens directly
into the uterus (Senger, 2003).
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1.4. STALLION REPRODUCTIVE ENDOCRINOLOGY
As in other mammalian species, normal testicular function in the horse is
dependent upon a functional pineal gland that produces and release melatonin and on a
hypothalamic-pituitary-testicular (HPT) axis (Roser, 2008). The major HPT hormones
involved in the control of the stallions’ reproductive functions are: the hypoyhalamic
gonadotropin-releasing hormone (GnRH); the hypophyseal luteinizing hormone (LH) and
follicle stimulating hormone (FSH); and, the testicular hormones such as testosterone,
estrogens and, inhibin (Gerlach and Aurich, 2000; Roser, 2008).

Melatonin and GnRH
Melatonin, a photoinducible hormone, is a seasonal regulator of reproductive
function secreted by the pineal gland. When released, during the non-breeding season,
melatonin suppresses production and release of GnRH by the hypothalamus. During the
breeding season melatonin production is low and consequently GnRH is high promoting
testicular function and sperm production (Gerlach and Aurich, 2000; Malpaux et al.,
2001; Sharp, 2011). It was shown, in stallions, that exogenous melatonin decreased
plasma testosterone concentrations (Argo et al., 1991).
The hypothalamus releases GnRH in a pulsatile manner and stimulates pulsatile
secretion of the pituitary hormones, LH and FSH, which act at the level of the testis.
Inhibin, estrogen and testosterone are secreted by the testis into the blood and act as
classical feedback regulators of hypothalamic and pituitary output (Roser, 2001, 2008).
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Luteinizing hormone
Luteinizing hormone is essential for male reproduction. Knockout male mice for
the LH ligand are infertile and show significant decreases in testes size, accessory gland
size, intra-testicular testosterone level and Leydig cell number (Kumar, 2005).
Luteinizing hormone binds to its receptor on the testis interstitial Leydig cells and
stimulates the secretion of testosterone and estrogens (Eisenhauer and Roser, 1995;
Gerlach and Aurich, 2000; Roser, 2008). In stallions, LH release has shown to be
positively correlated with day length. Even though pituitary LH concentrations are
constant throughout the year, basal plasma LH concentrations during the breeding season
are as high as twofold as LH concentrations during the winter months. Geldings do not
show change in plasma LH concentrations according to the time of the year, indicating
that the seasonal changes in LH release in horses require the presence of the gonads,
indicating a steroid-dependent effects of photoperiod (Gerlach and Aurich, 2000).

Follicle stimulating hormone
Follicle stimulating hormone binds to Sertoli cells, which stimulate production of
estrogens, inhibin, activin, androgen-binding protein (ABP), transferrin, insulin-like
growth factor-1 (IGF-1), and other factors needed for spermatogenesis (Roser, 2011).
Inhibin inhibits synthesis of FSH at the level of the pituitary in the mare. A
paracrine–autocrine role of inhibin, has not been well established in the stallion testes. In
the

stallion,

inhibin

has

been

localized

in

Leydig

and

Sertolli

cells

by

immunocytochemistry. In addition, it is believed to be important for testicular
recrudescence because peripheral FSH and inhibin exhibit similar seasonal changes:
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increase in the spring and decrease in the fall (Nagata and Tsunoda, 1998). Inhibin may
act in conjunction with testosterone and estrogen to control FSH secretion (Roser, 2011).
Activin has been shown to positively modulate the release of pituitary FSH in
other species, but its action in the stallion is unknown (Roser, 2011).

Testosterone
Testosterone is essential for maintaining and restoring spermatogenesis in adults,
affecting sexual drive (libido), stimulating metabolism, initiating and sustaining male
secondary sex characteristics, and supporting organs of the male reproductive tract
(Senger, 2003). Testosterone acts by binding to its receptors on Leydig and Sertolli cells
and exerts a negative feedback on the hypothalamus via the peripheral circulation and
inhibits synthesis and secretion of GnRH, but has no action on LH release at the level of
the pituitary (Roser, 2011).

Estrogens
The stallion testes produce large amounts of estrogens. Estradiol 17-β has been
shown to have an agonistic affect on the release of GnRH-induced LH secretion from the
pituitary gland (Muyan et al., 1993). However, the role of estrogens in regulating
pituitary FSH still remains unclear (Roser, 2011). Thompson and coworkers
demonstrated that treatment with estradiol decreased circulating FSH levels, increased
circulating LH levels, and decreased GnRH-induced FSH in geldings (Thompson et al.,
1979).
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1.5. SPERMATOZOA
The spermatozoon is a highly specified cell that has the abilities of active motility
and fertilization of the ovum. This cell is composed of head and flagellum (or tail), both
enclosed by a plasma membrane (Johnson et al., 1997)
The head can be subdivided into an acrosomal region, equatorial segment, postacrosomal region, and posterior ring; the latter demarcates the junction between the head
and tail. The two main structures of the sperm head are nucleus and acrosome. The
nucleus contains the male genetic material (DNA) to be delivered to the ovum and it is
surrounded by the nuclear envelope. Abnormal sperm chromatin structure may increase
the susceptibility of the sperm cell to denaturation and may also interfere with
decondensation, a prerequisite for male pronucleus formation during fertilization (Neild
et al., 2005; Baumber-Skaife, 2011).
The acrosome is a bag of hydrolytic enzymes required for penetration of the egg
during fertilization (acrosome reaction). Therefore, an integer acrosome is important to
ensure fertilization occurs (Neild et al., 2005; Varner, 2008). The acrosome is located
over the anterior surface of the nucleus and is surrounded by the inner and outer
acrosomal membranes. The acrosome can be divided into the apical segment, principal
segment, and equatorial segment (Johnson et al., 2011; Varner and Johnson, 2011).
The flagellum is anatomically divided into four parts: the neck region or connecting
piece, the middle piece, the principal piece and, the end piece (Johnson et al., 2011;
Varner and Johnson, 2011). Mitochondria, responsible for energy production, are located
in the middle piece. Mitochondria function is required for spermatozoa motility (Varner,
2008). The principal piece contains the fibrous sheath with rib-like structures for
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flexibility and is attached to the end piece. The tail is motile due to the presence of an
axoneme (nine microtubular doublets and a central pair of microtubules) for all its lenght.
The principal piece is the longest portion of the flagellum and contains a fibrous sheath,
which allows for bending during movement. The end piece is composed of unsheathed,
often single, microtubules (Johnson et al., 1997).
The spermatozoon is surrounded by a continuous and heterogeneous plasma
membrane, with regional differences in composition reflecting the different physiological
functions, such as sperm–oviductal adhesion, penetration of the cumulus–oophorus
matrix, sperm–zona adhesion, the acrosome reaction, acquisition of activated motility and
hyperactivated motility, and sperm–oocyte adhesion and fusion (Aurich, 2005; Varner
and Johnson, 2011). Therefore, an intact and functional plasma membrane is vital to both
sperm survival and fertilizing potential (Varner, 2008).
In the horse, spermatozoa are not mature when released from the seminiferous
tubules. They have a cytoplasmic droplet on its middle piece and must undergo
maturation in the epididymis to gain progressive motility, structural stability, and
fertilizing ability (Johnson et al., 1980). In the cytosol of the mature spermatozoal head
organelles are not found, other than the acrosome, and the mature spermatozoon is
considered to be transcriptionally quiescent (Varner, 2008; Varner and Johnson, 2011).

1.6. SPERMATOGENESIS
Spermatogenesis is the process by which germ cells (spermatogonia,
spermatocytes, and spermatids) in the seminiferous epithelium of the testes divide and
differentiate to produce spermatozoa (Johnson et al., 1997; Brito, 2007). Spermatogenesis
can be divided into three phases: (A) spermatocytogenesis (mitosis); (B) meiosis and, (C)
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spermiogenesis (Figure 1.3.3.). The total duration of spermatogenesis in the horse is 57
days, in which spermatocytogenesis lasts 19.4 days, meiosis also lasts 19.4 days and
spermiogenesis 18.6 days.

Figure 1.3.3. Spermatogenesis. Differentiation of a spermatogonium into a
spermatozoon: (1) Spermatocytogenesis; (2) Meiosis; and, (3) Spermiogenesis. (Modified
from:

http://faculty.clintoncc.suny.edu/faculty/michael.gregory/files/Bio%20100/Bio%

2010020 Lectures/Meiosis/meiosis.htm).

‘

1.6.1. Spermatocytogenesis
Spermatocytogenesis involves spermatogonia, the most immature germ cell.
Spermatogonia arise postnatally from gonocytes (positioned in precursos seminiferous
tubules during the second month of gestation) and are located in the base of the
seminiferous epithelium in adults.
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There are two types of spermatogonia: the stem cell spermatogonia
(uncommitted) and the committed spermatogonia. During spermatocytogenesis, the
committed cell population of spermatogonia proliferates cyclically by mitosis to produce
primary spermatocytes and at the same time the uncommitted spermatogonia renew their
own number and continue the lineage of stem cells (Figure 1.3.3.). There are five
subtypes of spermatogonia in the horse known as A1, A2, A3, B1, and B2 in the stallion.
These cells grow, differentiate and divide by mitosis until ultimately the B1
spermatogonia divide producing preleptotene primary spermatocytes.
Spermatocytogenesis lasts 19.4 days in stallions.

1.6.2. Meiosis
The meiotic phase includes the genetic recombination activity (crossing over) and
concludes with the production of haploid spermatids. Meiosis occurs only in germ cells in
the gonads (testes and ovaries) and in the male consists in the formation of haploid
secondary spermatocytes and haploid spermatids from the diploid primary spermatocytes
(Figure 1.3.3.). The preleptotene primary spermatocytes immediately begin meiosis I and
as different phases of meiosis are completed, they develop into leptotene, zygotene
(beginning of exchange of genetic material), pachytene, and diplotene primary
spermatocyte (prophase I). Diplotene primary spermatocytes, after prophase I, rapidly
undergo metaphase, anaphase, and telophase I. Secondary spermatocytes (n) result from
the first meiotic division. Meiosis II resumes and round spermatids (n) are generated.
Meiosis lasts 19.4 days in the stallion.
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1.6.3. Spermiogenesis
Spermiogenesis is a non-dividing period of spermatogenesis where round spermatids
elongate into spermatozoa (Figure 1.3.3.). It does not involve any cellular divisions
(DNA repair takes places and DNA synthesis is minimal) and rather it is the morphologic
differentiation of the haploid round spermatids into the unique mature sperm cells.
Spherical spermatids cells with spherical nuclei undergo metamorphosis and turn into
spermatozoa: a cell with a streamlined head containing penetrative enzymes and a
condensed nucleus carrying the male genome and a tail necessary for motility. The
process of spermiogenesis in stallions is 18.6 days long and is divided into Golgi, cap,
elongation, and maturation phases, depending on maturation changes within the
spermatid noted by shape and predominant organelles (Figure 1.3.4.).

Figure 1.3.4. Spermiogenesis
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Golgi phase spermatids have a prominent Golgi apparatus that gives rise to the
acrosome of the mature spermatozoon. During the cap phase, the acrosomic vesicle
flattens and begins to spread, forming a cap over the nucleus. The Golgi apparatus starts
moving away from the acrosome of the cell and flagellar development becomes more
obvious as it projects further from the cell’s surface. The nucleus is still spherical at this
time. As the cap extends over the nucleus, the nucleus begins to elongate and the
elongation phase initiates. A unique and transient spermatid organelle called manchette
elongates the nucleus and extends down to the developing flagellum, all within the
cytoplasm, which is also elongated.
The final phase of spermatid development (maturation) is characterized by caudal
migration and dissolution of the manchette. The manchette is not seen in a normal
spermatozoon. During maturation, mitochondria moves to the mid piece region. Upon
spermiation (release of fully developed spermatid into the lumen of seminiferous tubules)
a large portion of cytoplasm found in the spermatid is left behind, creating the residual
body, which is phagocytized and digested by its lysosome and by the Sertoli cells.
Sertolli cells also phagocytose any other germ cells that die during spermatogenesis.
After spermatogenesis, spermatozoa leave the testis and are transported through
the epididymis, where final maturation occurs and the spermatozoon gains ability of
motility and fertilization of an oocyte in a process that lasts 8-11 days in the stallion.
Therefore, sperm present in the ejaculated began being produced 65-68 days earlier and
semen quality is a reflection of events that have occurred in the past 2 months and
affected spermatogenesis and/or and final maturation of the sperm cell in the epididymis.
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1.6.4. Spermatogenic Cycle
The spermatogenic cycle is defined as a series of changes that occur in a given
region of the seminiferous epithelium between the appearances of the same
developmental stage. A stage, in turn, refers to the vast number of cells at the same level
of development (due to the existence of synchrony among germ cells) in a given region
of the seminiferous tubules. If we use spermiation as a reference point, the cycle would
be all the events that occur between two consecutive occasions of spermatozoa released
from a given region of the seminiferous epithelium. Thus, even though the
spermatogenesis is 57 days in the horse, spermatozoa are released every 12.2 days, which
corresponds to the duration of the spermatogenic cycle (Figure 1.3.5.).
The stallion spermatogenic cycle was divided into 8 stages and first described by
Swierstra et al. Classification of stages of the spermatogenic cycle has been based on the
presence and location of specific germ cells, and on changes associated with
spermiogenesis and spermiation (Swierstra et al., 1974).
While the spermatogenic cycle is the series of changes seen over time in a given
region of the tubule, the distribution of consecutive stages along the length of the tubules
at any given time is called spermatogenic wave.
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Figure 1.3.5. Three major phases of spermatogenesis. Spermatocytogenesis, meiosis,
and spermiogenesis are overlaid by the eight stages of the cycle of equine seminiferous
epithelium. During the 19 days required for spermatocytogenesis, A-spermatogonia (A)
enter cyclic activity during stage III and undergo division to produce B1 spermatogonia
(B1), B2 spermatogonia (B2), and preleptotene primary spermatocytes (Pl). During the
20 days of meiosis, newly formed preleptotene primary spermatocytes (Pl) differentiate
through leptotene (L), zygotene (Z), pachytene (P), and diplotene (D) before the first
meiotic division to produce secondary spermatocytes (SS), and the second meiotic
division to produce Sa spermatids (Sa). During the 18 days of spermiogenesis, Sa spermatids differentiate through Sb1 (Sb1), Sb2 (Sb2), Sc (Sc), Sd1 (Sd1), and Sd2 (Sd2)
steps of development before their spermiation as spermatozoa. The letters indicate the
cell type, while the numbers associated with the developmental step of each germ cell
indicate the total time to formation of that cell type, calculated to the middle of that
spermatogenic stage. In the horse, the cycle length is 12.2 days, and the duration of
spermatogenesis is 57 days (Johnson et al., 2011).
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III. JUSTIFICATION FOR THE THESIS RESEARCH PROJECT

The establishment of persistent infection in the reproductive tract of the infected
stallion is a unique feature of EAV infection. Persistently infected stallions play a very
important role in the dissemination and maintenance of EAV in horse populations
worldwide (Timoney et al., 1986; Timoney and McCollum, 1993a). In addition, the longterm carrier stallion is responsible for generating the genetic heterogeneity that
distinguishes individual field strains in contrast to the minimal virus diversity that is
generated during EVA outbreaks when the virus is transmitted by respiratory and or
venereal routes (Balasuriya, et al., 1999, 2004; Hedges et al., 1999).
Multiple factors may contribute to development of the carrier state in stallions.
However, even though it is known that EAV persistence in the reproductive tract of
stallions is testosterone dependent (Holyoak et al., 1993; Little et al., 1992; McCollum et
al., 1994), the reason(s) why some stallions become long-term carriers and some do not,
has never been elucidated. Using dual-color flow cytometry, previous studies in our
laboratory demonstrated the existence of two groups of horses based on their CD3+ T
lymphocyte cells susceptibility to in vitro infection with the virulent Bucyrus strain of
EAV (Go et al., 2010). Thus, the horse population can be divided into susceptible and
resistant groups based on the susceptibility of their CD3+ T cells to in vitro EAV. The
differences in in vitro susceptibility to CD3+ lymphocytes to EAV infection have a strong
association to genetic markers on equine chromosome 11 (Go et al., 2011). Furthermore,
carrier stallions with an in vitro CD3+ T lymphocyte susceptible phenotype may be at a
higher risk of becoming carriers following natural infection compared to those with the
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resistant phenotype (Go et al., 2012). Based on these observations, in the second chapter
of this thesis, we hypothesized that the establishment	
   of	
   persistent	
   infection	
   in	
  
stallions	
   is	
   associated	
   with	
   in	
   vitro	
   susceptibility	
   of	
   CD3+	
   T	
   lymphocytes	
   to	
   EAV	
  
infection. To test this hypothesis we investigated whether there is a relationship between
in vitro susceptibility of CD3+ T lymphocytes to EAV infection and the establishment of
persistent infection in stallions following experimental inoculation with the KY84 strain
of EAV.
Persistently infected stallions shed virus in semen for years following EAV
infection, but not in other bodily tissues and fluids. Thus, they are able to transmit the
virus only by venereal route. The long-term carrier stallion is clinically normal and has
normal semen quality, although virus persists in the reproductive tract and is shed in
semen. No long-term effects on stallions fertility have been observed on long-term carrier
stallions (Timoney and McCollum, 1993a). Previously, it has been shown that the semen
quality of acutely infected stallions was temporarily reduced, but it was not clear if this
decrease was due to the direct effect of virus present in semen (Neu et al., 1992). Several
viruses have been detected in the semen of a number of animal species and have been
shown to be detrimental to the male reproductive tract and to the semen (Sur et al., 1997;
Dejucq and Jégou, 2001). Therefore, in the third chapter of this thesis, we hypothesized
that changes in semen quality are the results of fever and scrotal edema caused by EAV
during acute phase of infection rather than the direct effects of the virus. To test this
hypothesis, we investigated if the possible changes observed in semen quality following
experimental EAV infection of stallions result either from the presence of virus in semen
or from the fever and scrotal edema caused by the virus during acute phase of infection.
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CHAPTER TWO
Association between in vitro CD3+ T cell susceptibility to EAV infection and EAV
persistence in stallions experimentally infected with the Kentucky 84 (KY84) strain
of EAV
2.1. SUMMARY
Equine arteritis virus (EAV) is the causal agent of equine viral arteritis (EVA), a
respiratory and reproductive disease of equids. Following EAV infection, a variable
proportion of stallions (30-70%) can become carriers and continuously shed the virus in
their semen for varying time periods. With the use of a dual-color flow cytometry it was
demonstrated that the virulent Bucyrus strain of EAV (VBS) could infect, in vitro, a
subpopulation of CD3+ T lymphocytes of some but not all horses.

Furthermore, a

correlation between in vitro susceptibility of CD3+ T lymphocytes to EAV infection and
long-term persistent infection among stallions following natural infections has been
shown. Here in this pilot study, we investigated whether the stallions with in vitro EAV
susceptible CD3+ T lymphocytes are at higher risk of becoming long-term carriers
compared to those with the resistant phenotype following in vivo experimental infection
with the KY84 strain of EAV. A group of eight stallions were divided into two groups
(n=4) based on their susceptible or resistant CD3+ T lymphocyte phenotypes and
intranasally inoculated with the EAV KY84.

Stallions were monitored for the

development of clinical signs of EVA, number of lymphocytes, and shedding of virus
into the nasal secretions and peripheral blood mononuclear cells (PBMCs) until 42 days
post infection (dpi). Semen was collected and evaluated monthly for he presence of EAV
until 198 dpi (6.5 months) to establish viral persistence. The data suggested that the

	
  

66	
  

establishment of long-term carrier state seems to be associated with the in vitro CD3+ T
lymphocyte susceptible phenotypes.

2.2. INTRODUCTION
Equine arteritis virus (EAV) is a small enveloped virus with a single-stranded
positive-sense RNA genome of 12.7 kb and is the prototype member of the family
Arteriviridae (genus Arterivirus, order Nidovirales (Cavanagh, 1997; Snijder and
Meulenberg, 1998; King et al., 2011). EAV is the causal agent of equine viral arteritis
(EVA), a respiratory and reproductive disease of equids (McCollum et al., 1971;
Timoney et al., 1987; Timoney and McCollum, 1993a). The virus was first isolated from
a lung of an aborted fetus following an extensive outbreak of respiratory disease at
Bucyrus, Ohio, U.S.A., in 1953 (Doll et al., 1957b; Doll, Bryans, and Knappenberger,
1957). There is only one known serotype of EAV and all strains evaluated thus far are
neutralized by polyclonal antiserum raised against the virulent Bucyrus strain
(Balasuriya et al., 1995, 1997, 2004; Chirnside, de Vries, et al., 1995; Balasuriya and
MacLachlan, 2004; Zhang et al., 2012). However, field strains of EAV can often be
distinguished on the basis of their neutralization phenotype with polyclonal antisera and
MAbs. Likewise, geographically, and temporally distinct strains of EAV differ in the
severity of the clinical disease they induce and in their abortigenic potential (Murphy et
al., 1992; Timoney and McCollum, 1993a; Balasuriya et al., 1998, 1999; Patton et al.,
1999; Vairo et al., 2012). While most EAV infections are asymptomatic, some infected
horses can exhibit clinical manifestations such as fever, leukopenia, dependent edema,
nasal and ocular discharge, conjunctivitis, and abortion (Doll, Bryans, and
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Knappenberger, 1957; McCollum et al., 1971, 1995; Glaser et al., 1996). The vast
majority of naturally infected adult horses recovers spontaneously and rarely dies from
the disease. However, following natural infection neonate and young foals can develop
severe interstitial pneumonia and pneumoenteritis and can die from EAV infection
(Golnik et al., 1981; Vaala et al., 1992; Del Piero et al., 1997). The virus is transmitted
mainly by respiratory (Doll, Bryans, and Knappenberger, 1957; McCollum et al., 1971)
or venereal routes (Timoney, 1984; Timoney, McCollum, Roberts, et al., 1986).
Following EAV infection, a variable proportion of stallions (30-70%) can become
carriers and continuously shed the virus in their semen for varying time periods
(Timoney, McCollum, Roberts, et al., 1986; Timoney et al., 1987; Neu and Timoney,
1988). The virus persists in the male reproductive tract, specifically in the ampulla of the
vas deferens (Neu and Timoney, 1988), despite the frequent presence of high titer
neutralizing antibodies in serum (Timoney, McCollum, Roberts, et al., 1986; Timoney et
al., 1987; Neu and Timoney, 1988).

The establishment and maintenance of EAV

persistence infection in male reproductive tract is testosterone dependent (Little et al.,
1992; Holyoak et al., 1993; McCollum et al., 1994).
In a recent study, using dual color flow cytometry we demonstrated that the
virulent Bucyrus strain (VBS) of EAV could infect in vitro CD3+ T lymphocytes from
some but not all horses (Go et al., 2010).

The data suggested that the CD3+ T

lymphocyte subpopulation of individual horses varied in their susceptibility to in vitro
EAV infection. Furthermore, a genome wide association study (GWAS) identified a
common, genetically dominant haplotype associated with the susceptible phenotype in
the region of equine chromosome 11 (ECA11; 49572804-49643932) (Go et al., 2011).
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As a result of this clearly defined genetic evidence, we hypothesized in a previous study
that in vitro susceptibility of CD3+ T lymphocytes to EAV infection may correlate with
the clinical responsiveness of horses to challenge with virulent strains of EAV. We
demonstrated that in vitro susceptibility/resistance of equine CD3+ T lymphocytes to
VBS correlated with the clinical responsiveness of horses experimentally inoculated with
recombinant VBS (rVBS). It was found that clinical signs are greater in horses that had
CD3+ T lymphocytes resistant phenotype compared to those that had a susceptible
phenotype when challenged with the rVBS of EAV (Go et al., 2012). In a parallel
retrospective study we demonstrated that there is a correlation between the stallion carrier
state of natural infected stallions and the in vitro CD3+ T cell susceptible phenotype (Go
et al., 2012). Based on these previous data, the specific aims of this study were: (1) to
investigate, prospectively, whether there is an association between in vitro CD3+ T
lymphocyte resistance/susceptible phenotypes of stallions and the establishment of
persistent infection of EAV in stallions following experimental inoculation with the
KY84 strain of EAV; (2) to evaluate the clinical response to in vivo EAV infection
among the CD3+ T cell susceptible and resistant in vitro phenotype stallions. The EAV
KY84 has been shown to establish persistent infection in the reproductive tract of
stallions and to cause moderate to severe clinical signs of EVA infection in horses
following natural and experimental infection (McCollum and Timoney, 1984; Timoney,
1984; Neu & Timoney, 1988; Zhang et al., 2012).
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2.3. MATERIAL AND METHODS
Viruses
The virulent Bucyrus strain of EAV (ATCC VR-796, Manassas, VA) was used to
identify the stallions with CD3+ T lymphocyte susceptible/resistant phenotype in
peripheral blood mononuclear cells as previously described (Go et al., 2011).

The

virulent KY84 strain of EAV (EAV KY84) was used as the challenge virus (McCollum
and Timoney, 1984, 1999; Timoney, 1984; Cole et al., 1986). The MLV vaccine strain
of EAV (ARVAC®, Pfizer Animal Health Inc., Kalamazoo, MI) was used as the
reference virus in the microneutralization assay. Virus stocks were titrated by standard
plaque assay in RK-13 cells, and titers were expressed as PFU/ml (McCollum et al.,
1962).

Cells lines
The high passage rabbit kidney cell line (RK-13 KY; passage level 399-409) was
maintained in Eagle’s minimum essential medium (EMEM; Cellgro®, Mediatech, Inc.,
Manassas, VA) supplemented with 10% ferritin-supplemented bovine calf serum
(Hyclone Laboratories, Inc., Logan, UT), 100 U/ml penicillin/streptomycin (Mediatech,
Inc., Manassas, VA) and 1 µg/ml amphotericin B (Sigma-Aldrich, St. Louis, MO).
Equine pulmonary artery endothelial cells (EECs; Hedges et al., 2001) were maintained
in Dulbecco’s modified essential medium (Cellgro®, Meditech, Inc., Manassas, VA) with
sodium pyruvate, 10% fetal bovine serum (FBS; Hyclone Laboratories, Inc., Logan, UT),
100 U/ml penicillin/streptomycin (Mediatech, Inc., Manassas, VA), and 200 mM Lglutamine (Invitrogen™, Carlsbad, CA).
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Antibodies
Monoclonal

antibodies

(MAbs)

were

used

to

identify

the

in vitro

susceptible/resistant phenotype of the CD3+ T lymphocytes of each of the stallions
following in vitro infection with the EAV VBS. The anti-equine CD3 MAb UC F6G
specific for CD3+ T lymphocytes was kindly provided by Jeff Stott, University of
California, Davis (Blanchard-Channell et al., 1994).

The R-PE conjugated F(ab’)

fragment of goat anti-mouse IgG1 (Southern Biotech, Birmingham, AL) was used as the
secondary antibody for the anti-equine CD3 surface marker. The EAV infected CD3+ T
lymphocytes were detected with Alexa Fluor 488-labled MAb 12A4 specific for the
nonstructural protein 1 (nsp1) of EAV (Wagner et al., 2003; Go et al., 2011).

Horses
Eight mature (4-16 years old) mixed breed stallions were included in the study
(Stallions L136-L143). In order to divide stallions into two groups based on the in vitro
susceptibility phenotype of their CD3+ T lymphocytes to the EAV VBS, a significant
number of stallions (n=15) were first screened by dual-color flow cytometry as
previously described (Go et al., 2010). A total of 8 stallions were selected and divided
into two groups according to their in vitro CD3+ T lymphocytes susceptible/resistant
phenotype to EAV VBS strain for use in this study: group A (susceptible [n=4; L136,
L138, L140, and L141]) and group B (resistant [n=4; L137, L139, L142, and L143])
(Figure 2.3.1.). Horses were obtained from a local commercial vendor and acclimated to
the new farm environment for approximately 2 months before the beginning of the study.
During this period animals were located in individual paddocks and trained to mount a
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mare or a phantom and to collect semen in an artificial vagina (Botucatu model,
Botupharma, Botucatu, SP, Brazil). All horses were confirmed seronegative for EAV
neutralizing antibodies several times before intranasal inoculation with the virus, using a
previously described protocol (Senne et al., 1985; OIE, 2004). The animals were then
housed in an isolation facility at the Department of Veterinary Science’s Maine Chance
Farm, Lexington, KY. This study was carried out in accordance with an Institutional
Animal Care and Use Committee (IACUC) approved protocol at the University of
Kentucky, Lexington, KY (protocol number 2011-0888).
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Figure 2.3.1. CD3+ T lymphocyte susceptible and resistant stallions’ phenotypes.
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Preparation of peripheral blood mononuclear cells
Equine peripheral blood mononuclear cells (PBMCs) from each of 8 stallions
were isolated as previously described (Go et al., 2010). Briefly, blood was collected
aseptically from each stallion in Vacutainer tubes containing 15% EDTA solution
(Kendall Healthcare, Masnfield, MA). PBMCs were isolated from the buffy-coat fraction
by centrifugation through Ficoll-Plaque™ PLUS (Amersham Biosciences, Piscataway,
NJ) at 500 × g for 30 minutes at 40C. The PBMCs layer was collected and washed twice
with PBS (pH 7.4) by centrifugation at 100 × g for 10 min to eliminate the platelets. The
remaining cells were resuspended in complete RPMI (cRPMI) 1640 medium (Gibco®,
Carlsbad, CA) supplemented with 10% heat-inactivated FBS (HyClone Laboratories,
Logan, UT), 2mM glutamine, 100U/ml penicillin/streptomycin, and 55 µM 2mercaptoethanol. PBMCs were counted using a Vicell Counter-XR (Beckman Coulter,
Miami, FL) and inoculated with EAV VBS at a multiplicity of infection (MOI) of 2.

In vitro infection of peripheral blood mononuclear cells
PBMC cultures, in 6-well plates (USA® Scientific Inc., Orlando, FL), were
infected with EAV VBS at an MOI of 2 as previously described (Go et al., 2010).
Infected cells were incubated at 370C in a CO2 incubator for 36h. As negative controls,
mock-infected PBMCs were cultured under identical conditions.

Dual-color immunofluorescence staining and flow cytometry analysis
Dual-color

flow

cytometry

was

used

to

analyze

the

in

vitro

susceptibility/resistance of each stallion’s CD3+ T lymphocytes to EAV VB strain as
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previously described (Go et al., 2010). Briefly, EAV infected and mock infected PBMC
cultures (approximately 1 × 106 cells) were incubated on ice for 30 minutes with the
equine CD3+ specific MAb UC F6G.

After washing, cells were incubated with

secondary R-PE-conjugated goat anti-mouse IgG1 for 30 min on ice. After washing to
remove unbound secondary antibody, cells were fixed with 4% paraformaldehyde and
then washed once in PBS-saponin buffer (PBS [pH 7.4] supplemented with 1% FBS,
0.1% saponin and 0.1% sodium azide). Intracellular staining for EAV antigen was
performed using an Alexa Fluor® 488 conjugated anti-EAV nsp1 MAb 12A4 in PBSsaponin buffer and incubated on ice for 30 min. After incubation, washed cells were
resuspended in PBS containing 0.5% paraformaldehyde for two-color cytometric
acquisition using a FACSCalibur (Becton Dickinson, San Jose, CA). Lymphocytes were
gated and selected based on forward and side-scatter parameters of analysis. Cells were
evaluated by a two-color plot of anti-EAV antigen (FL-1) versus cell surface antigen (FL2), and the percentage of CD3+ T lymphocytes and EAV antigen positive cells was
determined by CellQuest™ quadrant statistics. Results were expressed as the percentage
of lymphocytes infected with EAV, after subtraction of the non-specific staining of
mock-infected cells.

Experimental infection of stallions and clinical evaluations
The stallions in group A (susceptible: L136, L138, L140, and L141; n=4) and
group B (resistant: L137, L139, L142, and L143; n=4) were randomly assigned to
individual stalls in an isolation barn located at the University of Kentucky’s Maine
Chance Farm. All horses were clinically evaluated and several (6) blood samples for
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blood cell counts were collected prior to experimental infection (see below).

Pre-

inoculation (7, 5 and 2 days before experimental infection) clinical examinations were
performed once daily to determine base-line values for body temperature and to ensure
the stallions were clinically normal before inoculation with the virus.

Edema was

classified on a scale from 0 to 5 and recorded as absent (0), mild (1-2), moderate (3) and
severe (4-5). The stallions were inoculated intranasally with 3.75 × 105 plaque forming
units (PFU) of the KY84 strain of EAV in 5.0 ml of EMEM using a fenestrated catheter
passed via the posterior nares into the nasopharynx as previously described (Balasuriya et
al., 2007; Zhang et al., 2008). The animals were monitored for the appearance of clinical
signs of EVA twice daily (every 12 hours) for the first 2 weeks after infection. The
highest level of body temperature and the more severe clinical signs observed each day
were recorded. Clinical signs continued to be monitored once a week (one time a day)
for an additional 4 weeks of the experiment (at 21, 28, 35 and 42 dpi). All clinical
parameters were recorded by the same investigator who was blinded to the status of the
group each stallion belonged to. Blood samples were collected at 0 (before infection), 2,
4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 dpi in order to determine each stallion’s serum
neutralizing antibody response to EAV.	
  

Collection and process of clinical samples for virus isolation
Shedding of EAV in the semen, circulation and in the respiratory tract was
monitored following experimental EAV KY84 infection. Specifically, ejaculates were
collected from each horse at 2 days before infection, every other day for the first 15 days
of the experiment (1, 3, 5, 7, 9, 11, 13, and 15 dpi), and approximately once a month until
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6.5 months post-infection (23, 44, 65, 86, 107, 128, 149, 170, and 198 dpi). The raw gelfiltered semen samples were aliquoted and stored at -800C until virus isolation was
attempted (see below). Blood samples were collected at the day of infection, d 0 (before
infection), every other day for the first 15 days of the experiment (2, 4, 6, 8, 10, 12, and
14 dpi), and once a week until 42 dpi (21, 28, 35, and 42 dpi) for complete blood cell
counts and virus isolation from PBMCs. Nasal swabs were collected on same dates as
blood samples using sterile rayon swabs (1/2” × 1”) with plastic shafts (16”). After
collection, the tip of each swab was placed into 7ml of virus transport medium (VTM)
and kept on ice until transported to the laboratory. In the laboratory, each nasal swab
sample was squeezed and the VTM was placed in a sterile syringe and filtered through a
0.45µm filter. The filtrates were aliquoted and stored at -800C until subsequent attempted
virus isolation. All virus isolations were performed by the same investigator who was
blinded to the status of the group each stallion belonged to.

Clinical laboratory assays
Hematological analyses were performed at the Hagyard Equine Medical Institute
(4250 Iron Works Pike, Lexington, Kentucky) using an electronic cell counter (Coulter
Electronic Inc.). Differential counts were performed manually.

Virus Isolation – PBMCs and Nasal Swab
Virus isolation from PBMCs and nasal swabs was attempted on confluent
monolayers of RK-13 KY cells as previously described (Balasuriya et al., 2007; Zhang et
al., 2008).

	
  

Briefly, confluent RK-13 KY cells monolayers in 6-well plates (USA®
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Scientific Inc., Orlando, FL) were inoculated with 10-fold dilutions (100-10-5) in
duplicate

and

overlaid

with

supplemented

EMEM

containing

0.75%

carboxymethycellulose (CMC; Sigma-Aldrich, St. Louis, MO). Inoculated cells were
then incubated for 4 days at 370C in a CO2 (5%) incubator. At day 4 post-inoculation the
plates were checked under a light microscope for the presence of cythopatic effect (CPE).
If CPE was not visualized a second passage was performed on the 4th day. All first
passage 6-well plates were stained with a 1% crystal violet solution containing 1%
formaldehyde on day 4 post-inoculation for counting of plaques to determine the virus
titer (PFU/ml). The tissue culture fluid (TCF) samples from first and second cell culture
passages were harvested and stored at -80C, at day 4 post-inoculation.

Virus Isolation – Semen
Virus isolation from raw gel-free semen samples was attempted in RK-13 KY
cells according to a standard protocol used by the OIE Reference Laboratory at the
Maxwell H. Gluck Equine Research Center (OIE, 2004). Briefly, semen samples were
sonicated for 45 seconds (3 × 15 sec) at 40C and sperm and cellular debris were
sedimented by centrifugation (2,800 × g, 10 min). Serial decimal dilutions (10-1 to 10-4)
of each sample supernatant were prepared in minimum essential medium (MEM;
Cellgro®, Mediatech, Inc, Manassas, VA). One ml of each dilution was inoculated into a
25-cm2 flask containing confluent monolayers of RK-13 KY cells. Flasks were incubated
at 370C for 1 hour. Following incubation, flasks were overlaid with the supplemented
EMEM containing 0.75% carboxymethylcellulose (CMC; Sigma-Aldrich®, St. Louis,
MO).

	
  

The flasks were incubated at 370C for 4 days and checked under a light
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microscope for the appearance of CPE. If CPE was not detected, a second passage was
performed on that day. All first passage flasks were stained with a 1% crystal violet
solution containing 1% formaldehyde on day 4 post-inoculation. The plaques were
counted and virus titer was expressed as PFU/ml. Second passage flasks were also
stained with crystal violet 4 days after inoculation. The TCF samples from first and
second passages were harvested and stored at -80C.

Microneutralization assay
The neutralizing antibody titers of the test sera were determined as described by
Senne et al. (Senne et al., 1985; OIE, 2004). Briefly, duplicate serial two-fold dilutions
of each serum sample from 1:4 to 1:512 were made in supplemented EMEM containing
10% guinea pig complement (Rockland Immunochemicals, Gilbertsville, PA) and tested
in 96-well plates (Corning®, Corning Inc., NY). An equal volume of 200 TCID50 of the
modified live vaccine strain of EAV (ARVAC®, Pfizer Animal Health, New York, NY)
was added to each well. Plates were incubated at 370C in 5% CO2 for 1 hour. After
incubation, a suspension of RK-13 KY cells was added to each well and the plates were
incubated for 72 h, at 37°C, in a CO2 (5%) incubator, until viral cytopathic effect had
fully developed in the virus control wells. The titer of a sample was recorded as the
reciprocal of the highest serum dilution that provided at least 50% neutralization of the
reference virus.
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Real-time RT-PCR
Virus isolates were confirmed by EAV specific TaqMan® real-time RT-PCR
assay as previously described (Balasuriya, Leutenegger, et al., 2002; Miszczak et al.,
2011). Briefly, viral RNA was directly isolated from 50 µl tissue culture fluid (TCF)
using a commercial RNA isolation kit (MagMAXTM -96 Viral RNA Isolation Kit,
Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. The
viral RNA was eluted in 50 µl of nuclease free water and stored at −80 °C. RNA
extracted from TCF from PBMCs, nasal swab, and semen samples that were negative for
EAV, as well as from nuclease free water were included as negative controls. Viral RNA
extracted from a KY84 virus stock sample was used as a positive control. A one-tube
TaqMan® real-time RT-PCR assay was performed as previously described (Miszczak et
al., 2011).

2.4. STATISTICAL ANALYSIS
Locally weighted polynomials (LOWESS) were fit to the raw data for each
horse
then

to

produce

averaged

for

smooth
each

curves
group

(Cleveland,

separately,

1979).

with

standard

The

curves

errors

were

calculated

accordingly and used to construct pointwise confidence intervals. A t-test was performed
at the nadir or zenith of the curve to compare possible differences between the groups.
Significance was set as p < 0.05. All analyses were carried out using the R software for
statistical computing and graphics (www.r-project.org).
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2.5. RESULTS
Clinical Signs
All eight stallions developed moderate to severe clinical signs of EVA following
experimental infection with the KY84 strain of EAV, including any combination of fever
(> 38.60C), moderate to severe lymphopenia, dependent edema of the limbs, scrotum and
prepuce, periorbital edema, nasal and ocular discharge, photophobia, dyspnea, tacycardia,
anorexia, decreased libido and congestion, petechiae and ecchymosis of the oral mucous
membranes (Table 2.5.1.).

Table 2.5.1. Clinical findings in stallions following inoculation of stallions with the
KY84 strain of equine arteritis virus.

All stallions had fever ranging from 38.7 to 40.80C for 4-8 days (Table 2.5.2.).
Fevers (38.7-40.80C) were seen in group A stallions starting from 2-4 to 8-9 dpi and
between 1-3 and 8 dpi in group B stallions. Highest body temperatures were observed
among group A and group B stallions between 5-7 dpi and 6-7 dpi, respectively. The
highest body temperature (40.80C) was observed in group B, stallion L138 at 7 dpi, and
group A stallion L142 at 6 dpi.
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Table 2.5.2. Body temperature (0C) of group A and group B stallions before and after
inoculation with the KY84 strain of equine arteritis virus.

Yellow box * = fever (> 38.60C)
Orange box *** = highest body temperature for each stallion during acute phase of
infection

The body temperature across all stallions within a group was averaged for each
time point. The highest mean value of fever for group A stallions was observed at 7 dpi
while for group B stallions was at 8 dpi. On average, body temperature was not
statistically different between the two groups of horses (Figure 2.5.1.).
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Figure 2.5.1. Body temperature (0C) following inoculation of the stallions with the
KY84 strain of equine arteritis virus. (A) Individual body temperature values from
group A (red), and group B (blue) stallions. (B) Mean body temperature of stallions from
group A (red) and B (blue).
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The severity and duration of eyes, limbs, prepucial and scrotal edema varied
between stallions (Figure 2.5.2.).

Figure 2.5.2. Representative pictures of edema following experimental inoculation of
stallions with the KY84 strain of equine arteritis virus. (A) edema of limbs (stallion
L138; 8 dpi); (B) scrotal and preputial edema (stallion L140; 7 dpi); (C) periobirtal
edema with the presence of lacrimal discharge (stallion L138; 8 dpi); and, (D) erect penis
with preputial edema (stallion L140; 7 dpi).
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Periobirtal edema was seen in 3 out of 4 stallions belonging to group A (L138,
L140, and L141; 75%), starting from 2-4 dpi and lasting until 4-8 dpi (2-5 days), and in
only 1 group B stallion (L143; 25%) out of 4 between 1-6 dpi (Table 2.5.3.). Stallion
L138 (group A) was the only stallion in which periobirtal edema was severe on days 4
and 5 post infection.

Table 2.5.3. Periobirtal edema of group A and group B stallions before and after
inoculation with the KY84 strain of equine arteritis virus.

0 = edema absent
+ = edema is present
1 = unilateral
2 = bilateral
Green box + = mild edema
Blue box ++ = moderate edema
Red box +++ = severe edema
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Front and hind limb edema were observed in 3 of 4 stallions from group A (L138,
L140, and L141; 75%) and in all (L137, L139, L142, and L143; 100%) group B stallions
(Table 2.5.4.). The stallion belonging to group A (L136) who did not develop any
periobirtal edema also did not develop any edema of the front and hind limbs. Group A
and group B stallions developed front limb edema starting from 7-8 dpi and lasting until
13-15 dpi, and from 1-8 dpi to 11-14 dpi, respectively. Hind limb edema was seen in
stallions from group A starting from 0-7 dpi and lasting to at least 15-42 dpi.

Table 2.5.4. Edema of front (A) and hind (B) limbs of group A and group B stallions
before and after inoculation with the KY84 strain of equine arteritis virus.
A.
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Table 2.5.4. (continued)
B.

0 = edema absent
+ = edema is present
1 = unilateral
2 = bilateral
Green box + = mild edema
Blue box ++ = moderate edema
Red box +++ = severe edema

Five out of 8 stallions (group A: L138, L140, and L141; and group B: L137 and
L139) developed moderate to severe scrotal and preputial edema. Three of the group A
stallions (L136, L138, and L140; 75%) had edema of the scrotum/prepuce starting from
4-6 dpi to 13-15 dpi (3-9 days). Two stallions belonging to group A (L138 and L140)
had severe scrotal/preputial edema for 4-6 days (starting from 7-11 and lasting until 1112 dpi). Stallion L141 did not develop any dependent edema of the prepuce or scrotum.
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In stallions from group B, preputial and scrotal edema were observe only in 2 out of 4
animals (L137 and L139; 50%) starting from 4-6 dpi and lasting until 13-15 dpi (10
days). In this group of stallions severe preputial and scrotal edema was developed only in
stallion L137 and lasted for 5 days (Table 2.5.5.).

Table 2.5.5. Scrotal and preputial edema of group A and group B stallions before and
after inoculation with the KY84 strain of equine arteritis virus.

+ = edema is present
0 = edema absent
Green box + = mild edema
Blue box ++ = moderate edema
Red box +++ = severe edema

Stallions belonging to group A and group B developed a mucopurulent nasal
discharge during the acute phase of EAV infection (Figure 2.5.3.).
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Figure 2.5.3. Representative picture of mucopurulent nasal discharge following
experimental inoculation of stallions with equine arteritis virus. Stallion L142, at 3
dpi.

Three out of 4 stallions from group A (L136, L138, and L140; 75%) had a mild
mucopurulent nasal discharge starting from 5-6 dpi until 5-10 dpi (1 to 3 days) (Table
2.5.6.). Group B stallions also had 3 stallions (L139, L142, and L143; 75%) with mild to
moderate mucopurulent nasal discharge for 2-10 days (from 3-7 dpi to 8-13 dpi).
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Table 2.5.6. Mucopurulent nasal discharge in group A and group B stallions before and
after inoculation with the KY84 strain of equine arteritis virus.

0 = mucopurulent nasal discharge is absent
+ = mucopurulent nasal discharge is present
1 = unilateral
2 = bilateral
Green box + = mild mucopurulent nasal discharge
Blue box ++ = moderate mucopurulent nasal discharge

Inoculated stallions showed varying degrees of alteration of the oral mucosa
during the acute phase of EAV infection (Figure 2.5.4.).
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Figure 2.5.4. Representative pictures of changes in oral mucosa following
experimental inoculation of stallions with the KY84 strain of equine arteritis virus.
(A) congested oral mucosa (stallion L138; 6 dpi); (B) petechiae (stallion L140; 5 dpi);
(C) ecchymosis (stallion L141; 5 dpi); and, (D) nasal hemorrhage (stallion L140; 5 dpi).
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The most accentuated changes were seen in stallions from group A (Table 2.5.7.).
In this group, 2 stallions (L136 and L140; 50%) had petechiae in their oral mucosa from
5-6 dpi to 6-7 dpi (2 days); 1 stallion (L141; 25%) developed ecchymosis for 7 days (410 dpi); and, another stallion (L138; 25%) had congested oral mucosa for 2 days (6-7
dpi). Interestingly, stallion (L140) had a mild nasal hemorrhage at 5, 6, and 7 dpi. In
group B stallions such alterations were not observed, and only 2 out of 4 animals (L139
and L143; 50%) had oral mucosal congestion for 1-2 days (from 6-7 dpi).

Table 2.5.7. Appearance of oral mucosa in group A and group B stallions before and
after inoculation with the KY84 strain of equine arteritis virus.

0 = mucosa pigmentation within normal limits

All stallions from both group showed a decrease in libido during the acute phase
of infection. The time to drop the penis as well as the number of times each stallion had
to jump the mare or the phantom for ejaculation increased. All the clinical signs along
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with the moderate to severe edema in hind limbs of the stallions would have made it
difficult for them to mount, which contributed to the increased time to obtain the
ejaculate. However, none of seven stallions failed to mount the mare or the phantom.
One stallion from group B (L142) failed to ejaculate and instead, provided only the preejaculatory fluid at 1 dpi. One stallion from group B (L143) always had very low libido
and was never able to ejaculate, even though serum testosterone concentrations were
within normal limits (data not showed). All stallions seroconverted to EAV starting from
8 dpi and maintained high neutralizing antibody titers in serum until at least 42 dpi (1:64
to > 1:512).

Lymphocyte count
The number of lymphocytes across all stallions from each group was averaged for
each blood sample collection and compared to the baseline average before inoculation.
All stallions from both groups had on average, a baseline value within normal limits for
the number of lymphocytes (1.8-5.7 K/µL), with the exception of animal L143 from
group B, which showed a slightly low lymphocyte baseline mean of 1.3 K/µL previous to
experimental inoculation with the KY84 EAV (Table 2.5.8.)

All stallions had a

significant decrease (p < 0.05) in the number of lymphocytes following inoculation of the
animals with the virus.

However, one stallion (L136) belonging to group A, had

lymphocyte counts within normal limits throughout the experiment.
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Table 2.5.8. Lymphocyte counts (K/µL) in group A and group B stallions before and
after inoculation with the KY84 strain of equine arteritis virus.

Green box * = low lymphocyte counts (normal range: 1.8-5.7 K/µL)

On average, a decrease in the number of lymphocytes following experimental
infection of the stallions with the KY84 strain of EAV was observed between 8 and 28
dpi for group A and group B experimentally infected stallions (p<0.05) and no significant
differences were seen between the groups (Figure 2.5.5.).
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Figure 2.5.5. Lymphocytes count before and after inoculation of the stallions with
the KY84 strain of equine arteritis virus. (A) Individual lymphocyte values from group
A (red) and, group B (blue) stallions. (B) Mean lymphocyte counts from group A (red)
and B (blue) stallions. The shaded area corresponds to the 95% C.I.

A.

B.
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Virus Isolation
All eight stallions inoculated with EAV KY84 shed virus in nasal secretions,
PBMCs, and semen (with the exception of stallion L143 from who semen assessment was
not possible, as mentioned above) during the acute phase of EAV infection. Virus titers
in nasal swab secretions, PBMCs and semen, across all stallions within each group were
averaged for each time point. Virus titers varying between 1 and 5.7 × 104 PFU/mL in
group A nasal swab secretions from 2 to 10-21 dpi (9-20 days), and in group B stallions
titers between 1 and 4.2 × 104 PFU/mL from 2 to 10-14 dpi (9-13 days) (Table 2.5.9.).
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Table 2.5.9. Results of attempted virus isolation from nasal swabs collected from group
A and group B stallions before and after experimental inoculation with the KY84 strain
of equine arteritis virus.

0 Virus isolation negative in cell culture
++ Virus isolation positive on first passage in cell culture
§ Virus isolation positive only after second passage in cell culture

On average, the highest virus titer in nasal swab was seen at 6 dpi in group A
(2.05 × 104 PFU/mL) and group B (1.97 × 104 PFU/mL) stallions, and no statistical
differences in nasal swab viral shedding were found between the two groups at any time
point (Figure 2.5.6.).
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Figure 2.5.6. Mean viral titers (PFU/mL) in collected samples following inoculation
of the stallions with the KY84 strain of equine arteritis virus. (A) Nasal swab
secretions (NS); (B) PBMCs; and, (C) Semen samples (SS). The shaded area corresponds
to the 95% C.I.
A. NS

B. PBMCs
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C. SS

Similarly, on average, no significant differences were seen in virus titers detected
in PBMCs, with highest titers (group A: 1.49 × 103 PFU/mL and group B: 1.10 × 103
PFU/mL) being observed in both groups at 6 dpi (Figure 2.5.6.). Group A stallions
circulated virus (1 to 5.1 × 103 PFU/mL) in PBMCs from 13-27 days (2 to 14-28 dpi) and
all group B stallions circulated virus in PBMCs for 27 days (2-28 dpi) and titer varied
from 1 to 1.45 × 103 PFU/mL (Table 2.5.10.).
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Table 2.5.10. Results of attempted virus isolation from PBMC samples from group A and
group B stallions before and after experimental inoculation with the KY84 strain of
equine arteritis virus.

0 Virus isolation negative in cell culture
++ Virus isolation positive on first passage in cell culture
§ Virus isolation positive only after second passage in cell culture

On average, no significant differences were seen in virus titers shed in semen
from group A and group B stallions at different time points (Figure 2.5.6.); the highest
virus titers detected in semen within group A animals was 5.35 × 106 PFU/mL at 9 dpi
and within group B animals was 1.05 × 106 PFU/mL at 7 dpi. Stallions from both groups
started shedding virus in semen at 5 dpi; an exception was one group A stallion (L141)
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which shed detectable virus as early as 3 dpi. Seminal virus titers from group A stallions
varied from 1 to 1.88 × 107 PFU/mL and for group B stallions from 1 to 3.05 × 106
PFU/mL (Table 2.5.11.). All stallions from group A and B shed virus in semen until at
least 107 dpi (3.5 months). One stallion belonging to group A (L138; 25%) stopped
shedding virus somewhere between 107-128 dpi (3.5 and 4 months). Stallions L136,
L140, and L141 remained carriers of EAV until the end of the experiment (198 dpi; 6.5
months). Two out of three stallions from group B (L137 and L142; 66.6%) stopped
shedding virus in their semen sometime between 128-149 dpi and 170-198 dpi,
respectively. Stallion L139 (33.3%) remained infected until the end of the study, at 198
dpi (6.5 months). Interestingly, this stallion had a serious hind limb injury and started
being treated with a non-sterirodal anti-inflammatory (phenylbutazone) from 76 until 198
dpi. Stallion L143, as mentioned before, never ejaculated and unfortunately no semen
could be obtained to check the status of virus shedding in his semen.
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Table 2.5.11. Results of attempted virus isolation from gel-free semen samples of group
A and group B stallions before and after experimental inoculation with the KY84 strain
of equine arteritis virus.

0 Virus isolation negative in cell culture
++ Virus isolation positive on first passage in cell culture
§ Virus isolation positive only after second passage in cell culture
- Stallion failed to ejaculate
*** Missing sample - stallion was confirmed to be a carrier at 254 dpi

	
  

102	
  

2.6. DISCUSSION
The objective of the present study was to investigate whether there is a possible
association between susceptibility of CD3+ T lymphocytes and the establishment of virus
persistence in experimentally EAV infected stallions. Eight seronegative EAV stallions
were divided into two groups according to their susceptible/resistant phenotype (group A
= susceptible [n=4], and group B = resistant [n=4]) and intranasally inoculated with the
KY84 strain of EAV. Following KY84 EAV infection, the animals were monitored for
the development of clinical signs of EVA, circulation of the virus in PBMCs, and
shedding of the virus in nasal secretions and semen samples. The stallions were also
monitored for the establishment of the carrier state for a period of 6.5 months. In contrast
to the results of Go et al. (Go et al., 2012), in which clinical response and viremia
burdens were more pronounced in the group of stallion with the CD3+ T lymphocytes
resistant phenotype, in the present study, no differences in clinical response, shedding of
virus in nasal secretions and viremia were observed between the groups. All the stallions
in both groups developed clinical signs characteristic of EVA and the severity of these
changes did not vary much between the two groups. It is possible that the conflicting
results regarding development of clinical signs are the result of using different virus
strains for the experimental infection of the animals. Also, the viral titer in the semen of
the experimentally infected stallions during the acute phase of the infection was not
significantly different between group A (susceptible) and group B (resistant) stallions.
Establishment of the carrier state seems to be associated with the susceptibility of CD3+ T
lymphocytes to in vitro EAV infection. Three (L136, L140, L141) out of 4 stallions
(75%) belonging to group A (susceptible) became carriers of EAV and were still
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shedders of high titers of the virus, at least until 6.5 months following infection.
However, only one stallion out of the 3 (L139; 33%) that had a CD3+ T lymphocyte
resistant phenotype was still a carrier of EAV at 6.5 months after infection. Even though
a complete association between the CD3+ T lymphocyte resistant/susceptible phenotype
and the establishment of the carrier state in stallion was not conclusively established as
indicated in the retrospective study performed by Go et al., the results of both studies
suggest that stallions that have a susceptible CD3+ T cell phenotype are at higher risk of
becoming persistently infected than the stallions with CD3+ T cells resistant to in vitro
EAV infection. The flow cytometric analysis findings in this study did not provide a
perfect prediction of whether stallions exposed to EAV will or will not become a carrier
and shedder of the virus in semen. Interestingly, the only stallion that had a CD3+ T cell
resistant phenotype (L139) and was a carrier at 6.5 months post-infection (198 dpi),
developed an injury in one of his hind limbs and was treated with a non-steroidal antiinflammatory drug (phenylbutazone) from 76 until 198 dpi. Perhaps, the treatment had an
influence in the EAV persistence in the reproductive tract of this stallion, and therefore,
he shed virus in semen for longer compared to the other stallions belonging to the same
group (group B). Another possible reason for this stallion to keep shedding virus in
semen could be that 198 days was not enough time for him to clear the virus from the
reproductive tract, and maybe further semen collections (> 6.5 months after EAV
infection) would result in a negative virus isolation test and clearance of the carrier state.
The partial association between CD3+ T cell phenotype and the establishment of viral
persistence in the reproductive tract of stallion observed in this study could also be
explained by the fact that the stallions were experimentally infected with EAV rather than
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naturally exposed to the virus. The percentage of the CD3+ T lymphocyte population that
was susceptible to EAV infection in group A stallions ranged from 3.15% to 8.9%.
Interestingly, the only stallion that belonged to group A (CD3+ T lymphocyte susceptible
phenotype) and cleared virus from the semen, had only 3.15% of the lymphocyte cells
infected in vitro. The carrier stallions evaluated by Go et al. (2012) were all CD3+ T cell
susceptible, but all had at least 4% of the CD3+ T lymphocytes in vitro infected by EAV
VBS. Perhaps, there is a minimal amount of CD+ T lymphocytes that need to be infected
in vitro for a stallion to become a long-term carrier of EAV.
Recently, it was demonstrated in a genome-wide association study (GWAS) that
differences in the CD3+ T cells susceptibility are under genetic control since genes
located within the region of equine chromosome 11 (ECA11) positions 49572804 to
49643932 are associated with the in vitro susceptible CD3+ T cell phenotype (Go et al.,
2011). The authors focused on Thoroughbred horses since they have less diversity for
genetic markers than most other breeds of horses. In the present study, horses of mixed
breeds were used, and a possible explanation for the fact that a CD3+ T cell resistant
stallion was still a shedder at 6.5 months after infection could be that the genes of this
stallion that are responsible for the trait underwent mutation during evolution and so he
lacks susceptibility to in vitro EAV infection.
It is possible to conclude form this pilot study, that horses with a CD+ lymphocyte
susceptible phenotype seem to be at higher risk of becoming carrier stallions upon
infection with EAV. However, further studies to elucidate persistence of EAV infection
in the stallion are needed.
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CHAPTER THREE
Evaluation of semen quality of stallions challenged with the Kentucky 84 (KY84)
strain of EAV

3.1. SUMMARY
Equine arteritis virus (EAV) is the causal agent of equine viral arteritis (EVA), a
respiratory and reproductive disease of equids. Some strains of EAV cause fever and
scrotal and preputial edema during acute phase of infection. We hypothesized that fever
and scrotal edema observed during the acute phase of the infection will have a significant
effect on semen quality. A group of seven stallions were intranasally inoculated with the
KY84 strain of EAV. Stallions were monitored for clinical signs of EVA until 42 days
post infection (dpi). Semen was collected every other day for the first 15 days and 2
times a week up to 79 dpi. Three additional samples were collected at 147, 149 and 151
dpi. Semen from each stallion was evaluated on the basis of motility, total number of
spermatozoa, curvilinear velocity, membrane integrity and morphology. EAV titers in
semen samples were determined in RK-13 cells. There were significant decreases in
sperm quality from 11 to 76 dpi. Loess curves for each horse were fit and integrated to
quantify fever, virus and edema exposure over the 67 days period prior to each
ejaculation. Linear mixed models were then fit to isolate the effects of each factor on
semen quality. These models demonstrated strong evidence (p ≤ 0.002) that edema and
fever exert independent effects on all the semen quality parameters, but virus seems to
exert little to no direct effect, as virus titers remained high long after semen quality
returned to baseline.
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3.2. INTRODUCTION
Equine arteritis virus (EAV) is the causal agent of equine viral arteritis (EVA), a
respiratory and reproductive disease of equids. EAV was first isolated from a lung of an
aborted fetus in 1953 following an extensive outbreak of respiratory disease and abortion
in a Standardbred breeding farm at Bucyrus, Ohio (Doll et al., 1957a; Doll et al., 1957b).
The virus is transmitted mainly by respiratory (Doll et al., 1957b; McCollum et al., 1971)
and venereal routes (Timoney, McCollum, Roberts, et al., 1986). Most EAV strains
cause subclinical infection following infection of horses but some strains can cause
moderate to severe clinical signs (Prickett et al., 1972; Timoney and McCollum, 1993a;
McCollum et al., 1995; MacLachlan et al., 1996; Balasuriya et al., 1998, 2007; Patton et
al., 1999; Balasuriya, 2012; Zhang et al., 2012).

The clinical signs of EVA are

characterized by fever, nasal and ocular discharge, conjunctivitis, depended edema,
leukopenia and abortion (Doll, et al. 1957b; McCollum et al., 1971, 1995). The 1984
EVA outbreak in Thoroughbred breeding farms generated widespread interest and major
concern to the equine industry (Timoney and McCollum, 1993a). Epidemiological data
collected from that outbreak strongly suggested the establishment of a long-term
persistence of EAV in stallions and the importance of the carrier stallion in the
dissemination and perpetuation of the virus within the horse population (Timoney and
McCollum, 1985). Following EAV infection, a variable proportion of stallions (30-70%)
can become carriers and continuously shed the virus in their semen for varying time
periods (Neu and Timoney, 1988; Timoney et al., 1986, 1987). The virus persists in the
male reproductive tract, specifically in the accessory glands with highest titers being
found in the ampulla of the vas deferens (Neu and Timoney, 1988), despite the presence
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of high titer neutralizing antibodies in serum (Neu and Timoney, 1988; Timoney et al.,
1986, 1987). The mechanism of EAV persistence in the reproductive tract of stallions is
unclear, however it has been shown that establishment and maintenance of infection is
testosterone dependent (Little et al., 1992; Holyoak et al., 1993; McCollum et al., 1994).
Isolation of EAV from the pre-ejaculatory fluid from the semen of persistently infected
stallions was not successful and thus, virus is believed to be associated with the spermrich fraction of the ejaculate (Timoney et al., 1987). Persistently infected stallions play a
major role in the transmission of EVA to mares during natural breeding and artificial
insemination with fresh, cooled and frozen semen (Balasuriya et al., 1998, 1999;
Timoney et al., 1986, 1987). Recently, it has been demonstrated that under experimental
conditions, EAV can be transmitted to naïve recipient mares via embryo transfer from a
donor mare inseminated with EAV-infective semen (Broaddus et al., 2011).	
  	
  
Several viruses have been detected in the semen of a number of animal species,
some of which can exert direct or indirect detrimental consequences to the male
reproductive tract as well as to the semen (Sur et al., 1997; Dejucq and Jégou, 2001).
Little is known about the effects of EAV on the semen quality of stallions during acute
and persistent infection. Semen quality of stallions experimentally infected with EAV
was decreased for a period of time after inoculation with the virus but it was not clear if
the negative effect on semen parameters was due to the direct effect of the presence of the
virus in semen (Neu et al., 1992). Thus, the objectives of this study were to determine: 1)
if there is a significant effect on semen parameters of stallions experimentally infected
with the KY84 strain of EAV; 2) if the possible changes observed in the semen quality
result from direct effects of the virus present in semen or from the indirect effects of
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clinical signs (fever and scrotal edema) during the acute phase of infection with EAV.
The KY84 strain of EAV has been shown to establish persistent infection in the
reproductive tract of stallions and to cause moderate clinical signs of EVA infection in
horses (Neu and Timoney, 1988).

3.3. MATERIAL AND METHODS
Cells and viruses
The high passage rabbit kidney cell line (RK-13 KY; passage level 399-409) was
maintained in Eagle’s minimum essential medium (EMEM; Mediatech, Manassas, VA)
supplemented with 10% ferritin-supplemented bovine calf serum (Hyclone Laboratories,
Logan, UT), 100 U/ml penicillin/streptomycin (Mediatech, Manassas, VA) and 1 µg/ml
amphotericin B (Sigma-Aldrich, St. Louis, MO). The virulent KY84 strain of EAV
(EAV KY84) was used as the challenge virus (McCollum and Timoney, 1984, 1999;
Cole et al., 1986; McCollum et al., 1995). The modified live virus (MLV) vaccine strain
of EAV (ARVAC®, Pfizer Animal Health Inc., Kalamazoo, MI) was used as the
reference virus in the microneutralization assay.

Stallions
Seven sexually mature (4-16 years old) stallions of mixed breed were included in
the study (stallions IDs: L136 to L142). Horses were obtained from a local commercial
vendor and acclimated to the new farm environment for approximately 2 months before
the beginning of the study. During this period, animals were located in individual
paddocks and trained to mount a mare or a phantom and to collect semen in an artificial
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vagina. All stallions showed good libido and normal sexual behavior. All horses were
confirmed seronegative for EAV neutralizing antibodies several times before intranasal
inoculation with the virus using a previously described protocol (Senne et al., 1985; OIE,
2004). The animals were then housed in an isolation facility at the Department of
Veterinary Science’s Maine Chance Farm, Lexington, KY. The experiment described in
this manuscript was carried out in accordance with the Institutional Animal Care and Use
Committee (IACUC) approved protocol at the University of Kentucky, Lexington, KY
(protocol number 2011-0888).

Experimental infection of stallions and clinical examinations
The stallions were inoculated intranasally with 3.75 × 105 plaque forming units
(PFU) of the KY84 strain of EAV in 5.0 ml of EMEM using a fenestrated catheter passed
via the posterior nares into the nasopharynx as previously described (Balasuriya et al.,
2007; Zhang et al., 2008). The animals were monitored for the appearance of clinical
signs of EVA and shedding of the virus in the semen, in addition to semen quality
evaluation following experimental infection (see below). All clinical parameters were
taken by the same investigator. Scrotal edema was classified on a scale from 0 to 5 and
recorded as absent (0), mild (1-2), moderate (3) and severe (4-5). Pre-inoculation (7, 5
and 2 days before experimental infection) clinical examinations were performed once
daily to determine baseline values for body temperature and also to certify the parameters
were within normal limits before experimental infection of the stallions. Specifically,
fever and edema were monitored for the first 15 days after infection, twice daily (every
12 hours) and the highest value of the day was recorded. Clinical signs continued to be
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monitored once a week on the next 4 weeks of the experiment (at 21, 28, 35 and 42 dpi).
Blood samples were collected at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 dpi in order to
determine each stallion’s serum neutralizing antibody response to EAV.	
  

Semen collection
Two ovariectomized mares in behavioral estrus and previously vaccinated with
the commercial MLV vaccine (ARVAC®, Pfizer Animal Health, Inc., New York, NY)
(antibody titer = 1:256 and 1:512) against EVA were used to tease the stallions. Each
stallion was mounted either on the mare or on a breeding phantom for semen collection in
an artificial vagina (Botucatu model, Botupharma, Botucatu, SP, Brazil). The artificial
vagina was disinfected with an antiviral disinfectant (Roccal®-D Plus, Pfizer Inc., New
York, NY, USA) between collections and a disposable liner lubricated with sterile
lubricant (Priority Care, First Priority Inc., Elgin, IL, USA) was used for semen collection
of each stallion to avoid cross contamination between ejaculate samples. Semen was
collected from each stallion 3 times a week for a period of 3 weeks, and discarded, before
evaluation of samples started being performed.
Semen was then collected and evaluated 7, 5 and 2 days before infection as well
as every other day during the first 15 days after infection and twice weekly until 79 dpi.
Three additional samples were collected and evaluated at 147, 149 and 152 dpi. Preinoculation semen samples were obtained to determine base-line values for percentage of
total and progressively motile sperm cells (TMOT and PMOT), total number of
spermatozoa cells (TNS), curvilinear velocity (VCL), percentage of live spermatozoa
(LS), and percentage of morphologically normal spermatozoa (MNS). With the purpose
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of following virus persistence in the reproductive tract of the stallions, semen was
collected for virus isolation approximately once monthly until 198 dpi (6.5 months).

Semen processing and computer-assisted sperm analysis
Following collection, the total sperm number in gel-free semen was estimated by
measuring the volume with a graduated cylinder and the initial sperm concentration with
a spectrophotometer-based instrument (SpermaCue; Minitube of America Inc., Verona,
WI, USA). An aliquot of each ejaculate was fixed in 10% buffered formalin for analysis
of sperm morphology.

The gel-free semen was extended to approximately 25x106

spermatozoa/ml with a warm (370C) commercial skim milk-based extender containing
gentamicin (EQUIPRO®; Minitube of America Inc., Verona, WI, USA) and evaluated
using a computer-assisted sperm analysis (CASA) instrument (Sperm Vision® 3.5
Software; Minitube of America Inc., Verona, WI, USA) to determine the percent of
TMOT, PMOT and VCL. A 10 µL aliquot of extended semen was placed on a warmed
(370C) glass slide and overlaid with a warmed (370C) 22 × 22 mm cover slip. The slide
was then placed in a warmed stage microscope connected to a computer and spermatozoa
motion characteristics were analyzed. A total of 6 microscopic fields were examined per
sample by the same examiner each time.

Membrane Integrity
The integrity of the spermatozoa plasmatic membrane was determined using
eosin-nigrosin staining (Hancock Stain; Animal Reproduction Systems, Dupree Inc.,
Chino, CA, USA). Duplicate smears stained with the Hancock stain were prepared for
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spermatozoa membrane integrity evaluation (Hancock, 1951).

Briefly, 10 µl of the

Hancock stain solution was placed on the end of a warmed (370C) glass slide. A 5µl drop
of semen was placed next to the stain and the drops were mixed gently with the tip of a
pipette. With the use of another slide a smear of the mixture was created. The smear was
air-dried and observed under a microscope for analysis of the plasma membrane integrity.
The percentage of live spermatozoa (LS) was determined by counting 200 cells
throughout the slide for each of the two slides and the average number of live (unstained)
versus dead (stained) cells was recorded. When the number of sperm cells was low due
to low concentration of the sample, less than 200 spermatozoa were counted and the
percentage number was recorded. All slides were prepared and counted by the same
individual who was blind to the samples that were being analyzed.

Sperm Morphology
Sperm morphology (normal morphology, head, acrosome, mid-piece and tail
abnormalities, detached heads and proximal and distal droplets) was assessed by
differential-interference contrast microscopy (Axio Imager Upright Microscope). For
analysis, 1.5µL aliquots of fixed semen were applied to a microscope slide and then
overlaid with a cover glass.

Individual spermatozoa were assigned to only one

morphological category even if they exhibited several abnormalities. When more than
one defect was seen in the same sperm cell the more proximal defect was recorded. A
total of 100 sperm cells per sample were examined. All slides were counted by the same
individual who was blind to the samples that were being analyzed.
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Virus Isolation
Virus isolation from raw gel-free semen samples was attempted in RK-13 KY cell
lines according to the gold standard protocol used by the OIE Reference Laboratory
(OIE, 2004). Briefly, semen samples were sonicated for 45 seconds (3 × 15 sec) at 40C
and sperm and cellular debris were sedimented by centrifugation (2,800 3 × g, 10 min).
Serial decimal dilutions (10-1 to 10-4) of each sample supernatant were prepared in
minimum essential medium (MEM; Cellgro®, Mediatech, Inc, Manassas, VA). One ml
of each dilution was inoculated into a 25-cm2 flask containing confluent monolayers of
RK-13 KY cells grown in supplemented EMEM. Flasks were incubated at 370C for 1
hour.

Following incubation, flasks were overlaid with the supplemented EMEM

containing 0.75% carboxymethylcellulose (CMC; Sigma-Aldrich, St. Louis, MO). The
flasks were incubated at 370C for 4 days and checked on a microscope for the appearance
of cytopathic effect (CPE). If CPE was not detected, a second passage was performed on
day 4. All first passage flasks were stained with a 1% crystal violet solution containing
1% formaldehyde on day 4 post-inoculation for plaques counting and consequently virus
titration. Second passage flasks were also stained 4 days after inoculation for detection
of CPE. The same individual performed all virus isolations.

Microneutralization assay
The neutralizing antibody titers of the test sera were determined as described by
Senne et al. (1985). Briefly, duplicate serial two-fold dilutions of each serum sample
from 1:4 to 1:512 were made in supplemented EMEM containing 10% guinea pig
complement (Rockland Immunochemicals, Gilbertsville, PA) and tested in 96-well
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plates. An equal volume of 200 TCID50 of the modified live vaccine strain of EAV
(ARVAC®, Pfizer Animal Health, New York, NY) was added to each well. Plates were
incubated at 370C in 5% CO2 for 1 hour. After incubation, a suspension of RK-13 KY
cells was added to each well and the plates were incubated for 72 h at 37°C, until viral
cytopathic effect had fully developed in the virus control wells. The titer of a sample was
recorded as the reciprocal of the highest serum dilution that provided at least 50%
neutralization of the reference virus.

Real-time RT-PCR
Virus isolates were confirmed by EAV specific TaqMan® real-time RT-PCR
assay as previously described (Balasuriya et al., 2002; Miszczak et al., 2011). Briefly,
viral RNA was directly isolated from 50µl tissue culture fluid (TCF) using a commercial
RNA isolation kit (MagMAXTM -96 Viral RNA Isolation Kit, Applied Biosystems, Foster
City, CA) according to the manufacturer’s instructions. The viral RNA was eluted in 50
µl of nuclease free water and stored at −80 °C. RNA extracted from TCF from semen
samples that were negative for EAV as well as from nuclease free water were included as
negative controls. Viral RNA extracted from a KY84 virus stock sample was used as a
positive control.

A one-tube TaqMan® real-time RT-PCR assay was performed as

described in Miszczak et al., 2011 (Miszczak et al., 2011).

3.4. STATISTICAL ANALYSIS
Locally weighted polynomials (LOWESS) were fit to the raw data for each
horse to produce smooth curves (Cleveland, 1979). To quantify spermatozoa exposure
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to each potentially causative factor (fever, edema, virus concentration), these curves were
then

integrated

over

the

67-day

period

prior

to

each

sperm

quality

measurement. Regression models were then fit for each semen quality outcome to
determine the effects of each explanatory factor while adjusting for the other factors. To
account for within-stallion correlation among the measurements, linear mixed effect
models were used. All analyses were carried out using R software for statistical
computing and graphics (www.r-project.org). A two-sample t-test was used to compare
the differences between pre-virus-inoculation and post-virus-inoculation semen quality
parameters. Significance was set as p < 0.05.

3.5. RESULTS
Clinical signs
All seven stallions developed moderate to severe clinical signs of EVA following
experimental infection with the KY84 strain of EAV which included any combination of
fever (> 38.60C), moderate to severe lymphopenia, dependent edema of the limbs,
scrotum and prepuce, periorbital edema, nasal and ocular discharge, photophobia,
dyspnea, anorexia, decreased libido and, congestion, petechiae and ecchymosis of the
oral mucous membranes. All stallions had fever ranging from 38.70C to 40.80C starting
from 1-2 dpi and lasting until 8-9 dpi

(5-8 days) (Table 3.5.1.).

Highest body

temperatures were observed among the stallions between 5 to 7 dpi and the highest body
temperature (40.80C) was observed in stallion L138 at 7 dpi. On average, fever was
observed from 3 to 8 dpi (Figure 3.5.1.).
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Table 3.5.1. Body temperature of stallions (0C) before and after inoculation with the
KY84 strain of equine arteritis virus.

Yellow box * = fever (> 38.60C)
Orange box *** = highest body temperature for that stallion during acute phase of
infection
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Figure 3.5.1. Body temperature of stallions (0C) following experimental inoculation
with the KY84 strain of equine arteritis virus. (a) Average smoothed curve of body
temperature of stallions. The shaded area represents the 95% confidence interval. (b)
Smoothed curve of stallions’ individual body temperature.

a.

b.

The severity and duration of edema varied between stallions. Five out of 7
stallions (L136-L140; 71.43%) developed moderate to severe scrotal edema starting from
4-7 dpi and persisting until 9-15 dpi (Table 3.5.2.). Scrotal edema was observed, on
average, from 4 dpi until 15 dpi (Figure 2.5.2.).

	
  

118	
  

Table 3.5.2. Scrotal edema of stallions before and after inoculation with the KY84 strain
of equine arteritis virus.

+ = edema is present
0 = edema absent
Green box + = mild edema
Blue box ++ = moderate edema
Red box +++ = severe edema
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Figure 3.5.2. Scrotal edema following inoculation of stallions with the KY84 strain
of equine arteritis virus. (a) Average smoothed curve of scrotal edema exposure. The
shaded area represents the 95% confidence interval. (b) smoothed curve of individual
stallions scrotal and preputial edema. For the purpose of this graphic: 0 = no edema; 1 =
mild edema; 2 = moderate edema; and, 3 = severe edema. Note that edema was not seen
in all stallions, and thus the average is an oversimplification of the data.

a.

b.

Two of the five stallions (L136 and L139) had moderate edema for 3-5 days (7-11
dpi); three of the five stallions (L137, L138 and L140) had severe edema for 4-6 days (712 dpi) (Figure 3.5.3.).
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Figure 3.5.3. Representative example of severe scrotal and preputial edema
following experimental inoculation of stallions with the KY84 strain of equine
arteritis virus. Stallion L140 at 7 days post infection (dpi).

Two stallions (L141 and L142) did not develop any edema of prepuce or scrotum.
Stallion L141 had hemospermia following EAV inoculation, specifically at 11, 13 and 15
dpi. This stallion had a small wound in the gland of the penis. Even though the wound
persisted when blood was still observed in the semen, it is not possible to be sure if
hemospermia was associated with EAV infection. All stallions showed decreased libido
during the acute phase of infection. The time to drop the penis as well the number of
times each stallion had to jump the mare or the phantom for ejaculation increased. All
the clinical signs along with the moderate to severe edema in hind limbs of the stallions
observed during the acute phase of infection would have made it difficult for them to
mount, which contributed to the increased time to obtain the ejaculate. However, none of
the seven stallions failed to mount the mare or the phantom. One stallion (L142) failed to
ejaculate and instead, provided only the pre-ejaculatory fluid at 1 and 30 dpi. All
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stallions seroconverted to EAV starting from 8 dpi and maintained high neutralizing
antibody titers in serum until at least 42 dpi (1:64 to > 1:512).

Evaluation of semen for virus shedding
Following experimental inoculation of the stallions with EAV KY84, semen
samples from each stallion were tested for EAV shedding by virus isolation (VI) in cell
culture until 198 dpi. All stallions shed EAV in their semen starting at 3 dpi and
continued to shed at least until 107 dpi (3.5 months) (Figure 3.5.4.).

Figure 3.5.4. Virus titer in semen following inoculation of stallions with the KY84
strain of equine arteritis virus. (a) Average smoothed curve of virus titer in semen; and,
(b) smoothed curve of virus titer in semen of individual stallions.
a.

	
  

b.
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The virus titers in their semen varied from 1 × 101 to 1.88 × 107 PFU/ml during
the acute phase of infection. Following the acute phase of infection, all seven stallions
continued to shed very high titers of virus in their semen until 107 dpi, with the exception
of stallions L138 and L137, who shed low titer virus equivalent to 6 × 101 PFU/ml and 8
× 101 PFU/ml, respectively, at 107 dpi. Those stallions (L138 and L137) were no longer
carriers at 128 and 149 dpi, respectively. Stallion L142 stopped shedding virus sometime
between 170 and 198 dpi. Four out of 7 stallions (57%) kept shedding high titer virus at
least until 198 dpi (L136, L139, L140 and L41).

Evaluation of semen quality parameters
A total of 201 sequential semen samples (29 samples per stallion from stallions
L136 to L141, and 27 samples from stallion L142) from all seven stallions were collected
over a period of 12 weeks and these included 21 samples (3 per stallion) prior to the
experimental inoculation of stallions with the KY84 strain of EAV. Only one stallion
(L142) failed to ejaculate at 1 and 30 dpi. Three semen samples from each stallion
collected prior to experimental infection (-7, -5 and -2 days) were used to establish the
normal semen characteristics (baseline values) for total number of spermatozoa (TNS)
per ejaculate, total and progressive sperm motility (TMOT and PMOT, respectively),
curvilinear velocity (VCL), percentage of live sperm cells (LS), and percentage of
morphologically normal spermatozoa (MNS).

Before inoculation the mean baseline

values for TNS, TMOT, PMOT, VCL, LS, and MNS were 5.87 × 109 spermatozoa ± 0.05
× 109; 75.63% ± 2.24; 66.14% ± 3.62; 141.61 µm/s ± 9.43, 90% ± 0.01; and, 53.52% ±
3.59, respectively. Deterioration of at least one of the parameters analyzed for semen
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quality was observed in all stallions after inoculation with the KY84 strain of EAV
(Figure 3.5.5.).

Figure 3.5.5. Smoothed curve of the changes seen in semen quality parameters of
individual stallions following experimental inoculation with the KY84 strain of
equine arteritis virus. (a) total motile spermatozoa (% TMOT); (b) progressive motile
spermatozoa (% PMOT); (c) total number of spermatozoa (TNS); (d) curvilinear velocity
(VCL); (e) percentage of live spermatozoa (%LS); and, (f) morphologically normal
spermatozoa (% MNS).

a. %TMOT

	
  

b. %PMOT
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c. TNS

d. VCL

e. %LS

f. %MNS
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With the exception of one stallion (L141), TMOT, PMOT, VCL, TNS and
percentage of LS followed a similar trend in all other 6 stallions. Stallion L141, showed
a significant drop only in MNS following experimental inoculation with the EAV KY84,
but never showed a significant decrease in the other semen parameters (TMOT, PMOT,
TNS and percentage of LS). The alteration in the number of morphological normal
spermatozoa followed a similar trend in all 7 stallions, including L141.

Computer-assisted sperm analysis and evaluation of total number of spermatozoa
The percentage of TMOT, PMOT, VCL, and TNS across all stallions were
averaged for each collection and compared to the baseline average before inoculation
with the EAV KY84.
On average, semen motility decreased (TMOT and PMOT) between 20 and 65
dpi (p < 0.05) (Figure 3.5.6.). There was more than 50% reduction in TMOT and PMOT
of sperm between 30-51 dpi. Sperm motility (TMOT and PMOT) returned to preinoculation values around 65 dpi (Table 3.5.3.). Stallion L141 never showed a significant
drop in total or progressive motility following experimental infection with the virus. EAV
infection of the stallions also had an effect on VCL of sperm cells, with mean value
decreases being observed between 23 and 30 dpi (p < 0.05) (Figure 3.5.6.). TNS reduced,
on average, between 44-69 dpi (p < 0.05).

Two stallions, L139 and L142, had

azoospermia at 34, 37, 41, 48, 51, 55 dpi, and 44, 48, 51 dpi respectively (Figure 3.5.5.).
The TNS count returned to baseline values at around 69 dpi (Table 3.5.3.).
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Figure 3.5.6. Averaged smoothed curve of the changes seen in semen quality
parameters following experimental inoculation of stallions with the KY84 strain of
equine arteritis virus. (a) total motile spermatozoa (% TMOT); (b) progressive motile
spermatozoa (% PMOT); (c) total number of spermatozoa (TNS); (d) curvilinear velocity
(VCL); (e) percentage of live spermatozoa (%LS); and, (f) morphologically normal
spermatozoa (% MNS). The shaded area represents the 95% confidence interval.
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b. %PMOT

c. TNS
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e. %LS

f. %MNS

Table 3.5.3. Period of reduced semen quality in stallions following infection with the
KY84 strain of equine arteritis virus (a) Decrease in semen parameters; (b) Increase in
spermatozoa morphological abnormalities. Note that this is an oversimplification table
based on a two-sample t-test statistical analysis and not all stallions had necessarily a
change in all parameters evaluated.
a. Semen parameters

b. Spermatozoa morphological abnormalities

	
  

128	
  

Membrane Integrity
The percentage of spermatozoa with intact plasmatic membrane (live
spermatozoa; LS) across all stallions were averaged for each collection and compared to
the baseline average before inoculation with the EAV KY84. Before inoculation of the
stallions with the virus, all had at least 81% of LS and the mean baseline value for LS
was 90% ± 0.01 (Figure 3.5.5.). Changes in membrane integrity observed following
experimental infection of the stallions with EAV KY84 followed a similar trend in all
stallions, with the exception of stallion L141 as mentioned above. After inoculation,
damage of the plasmatic membrane was observed in the spermatozoa of all stallions
starting at 13 dpi. On average, decreases in the number of LS were significantly different
from baseline between 13-23 dpi (p < 0.05) (Figure 6). Recovery of membrane integrity
occurred at around 23 dpi (Table 3.5.3.).

Evaluation of sperm morphology
The percentage of MNS across all stallions were averaged for each collection and
compared to the baseline average before inoculation with the EAV KY84.
With the exception of two stallions (L136 and L141), others had at least 50%
MNS prior to experimental inoculation. Stallion L136 had 48% of MNS while stallion
L141 had only 41% MNS. All stallions showed reduction in the percentage of MNS
starting from 9-15 dpi. Percentage of MNS returned to normal values in all animals
ranging from 73-79 dpi with the exception of one stallion (L137). Stallion L137 showed
improvement in the number of MNS starting from 62 dpi and increasing until 79 dpi.
However, the percentage of MNS for this stallion did not return to baseline values during
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the time of the study (Figure 3.5.5.). On average, MNS was decreased as early as 11 until
76 dpi (p < 0.05) (Figure 3.5.6.) and recovered to normality around 76 dpi (Table 3.5.3.).
Spermatozoa morphological abnormalities followed a similar trend in all 7 stallions,
including L141.
The formalin fixed ejaculate aliquot was examined for the presence of
spermatozoa abnormalities as: head, acrosome, mid-piece and tail defects, as well as for
the presence of detached spermatozoa and proximal and distal droplets (Figure 3.5.7.).
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Figure 3.5.7. Representative picture of morphological abnormalities observed in
spermatozoa following experimental inoculation of stallions with KY84 strain of
equine arteritis virus. (a) Normal spermatozoa; (b) detached spermatozoa; (c) mid-piece
abnormality (bent); (d) tail abnormalities (bent and coiled); (e) proximal droplet; (f) distal
droplet; (g) head abnormality; (h) acrosome abnormality; and, (i-m) multiple
abnormalities on the same spermatozoon. 10% formalin fixed non-stained semen samples
viewed by differential interference contrast (DIC) microscopy.

Spermatozoa abnormalities across all stallions were averaged for each collection
and compared to the baseline average before inoculation with the EAV KY84. Before
inoculation of the stallions with the KY84 strain of EAV baseline values for all sperm
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cell abnormalities were seen on a frequency lower than 10%, with the exception of midpiece defects, which were observed on a high frequency (25.10%). An increase in a wide
variety of spermatozoa morphologic alterations was observed after inoculation of the
stallions with EAV KY84 and individual abnormalities were often, higher than 10%. The
abnormalities that mostly increased after the infection of the stallions were detached
heads, followed by head and proximal droplet defects, tail, distal droplets, mid-piece and
finally, acrosome (Figure 3.5.8.).

Figure 3.5.8. Averaged smoothed curve of the spermatozoa abnormalities (%)
following experimental inoculation of stallions with the KY84 strain of equine
arteritis virus. (a) Detached spermatozoa; (b) head abnormalities; (c) proximal droplets;
(d) distal droplets; (e) mid-piece abnormalities; (f) acrosome abnormalities; and, (g) tail
abnormalities.

a. Detached spermatozoa

	
  

b. Head abnormalities
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c. Proximal droplets

d. Distal droplets

e. Mid-piece abnormalities

f. Acrosome abnormalities

g. Tail abnormalities
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Even though there was an increase in acrosome and tail defects, those
abnormalities were never detected at a frequency higher than 10%. On average, there
was a 11-fold increase in the number of detached heads at 41 dpi (22.33%). The number
of detached heads was increased from 15-72 dpi and it was higher than 10% from 20-58
dpi. At around 72 dpi the percentage of detached spermatozoa returned to baseline
values (Table 3.5.3.). The head defects were observed to increase 6-fold at 51 dpi
(23.17%) compared to the mean value before inoculation of the stallions with the virus.
Abnormalities of sperm heads increased between 23-69 dpi (p < 0.05), however only
between 23-58 dpi were values higher than 10% observed. A 3-fold increase in the
presence of proximal droplets in spermatozoa was observed at 20 dpi (17.71%). The
percentage of proximal droplets increased from 13-27 dpi (p < 0.05) being higher than
10% also between 13-27 dpi. An increase in the number of spermatozoa showing distal
droplets was observed between 9-11 dpi (3-fold increase at 9dpi; 15.86%) (p < 0.05). At
9 and 11 dpi distal droplets were seen, on average, at a frequency higher than 10%.
However, between 20-58 dpi a decrease in the percentage of distal droplets was seen (p <
0.05).

Even though mid-piece abnormalities baseline values were observed at high

frequency (25.10%), the percentage of mid-piece spermatozoa defects seen in the
stallions’ ejaculate was increased between 62-65 dpi, after inoculation of the stallions
with the EAV KY84 (p < 0.05). During the period of the most dramatic decrease (23-58
dpi) in the percentage of MNS, individual sperm, frequently had 3 or more abnormalities,
even though only the most proximal was counted (Figure 3.5.7.).
In summary, following inoculation of the stallions with the KY84 strain of EAV
all stallions had a significant decrease in the number of morphological normal
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spermatozoa accompanied by a consequent increase in the number of spermatozoa
abnormalities. Stallion L141 did not show any change in the semen quality parameters
evaluated, other than a decrease in the percentage of morphologically normal
spermatozoa. On average, alteration in semen morphology occurred between 11 and 76
dpi.

Effects of fever, edema and virus on semen quality
The statistical data analysis demonstrated strong evidence that high body
temperature as well scrotal and preputial edema exert independent effects on all the
semen quality parameters. However high titer virus in semen during acute or persistent
infection of the stallions has little or no effect on semen quality (Figure 3.5.9.). Although
increased virus concentrations were consistently associated with lower semen quality, the
effect was usually not significant.
Scrotal edema and fever seem to have a larger effect on semen quality than virus
titers in semen. The statistical models estimate that a 1 standard deviation (SD) change in
temperature exposure, keeping edema and virus constant, would result in approximately
15% drop in normal morphology (p < 0.0001), 10% in TMOT (p < 0.001), and 12% in
PMOT (p < 0.001) compared to baseline. Whereas, a estimated change of 1 SD in edema
exposure keeping temperature exposure and virus concentrations constant, would result
in a drop of 23% normal spermatozoa morphology (p < 0.0001), 17% TMOT (p <
0.0001), 20% PMOT (p < 0.0001), 7% TNS (p < 0.01), 4% in the number of LS (p <
0.01), and 8% in VCL (p < 0.001) compared to baseline. A one standard deviation change
in virus concentration, though, keeping temperature and edema constant, would result in
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only 7.5% drop in TNS (p < 0.01) and, 2% in the number of LS (p < 0.03) but would not
have a significant effect in other semen parameters, such as, MNS, TMOT, PMOT and,
VCL.

Figure 3.5.9. Depiction of body temperature, scrotal and preputial edema and semen
virus titers along with semen quality parameters.
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3.6. DISCUSSION
The results of the present study demonstrated that semen parameters are
negatively affected following experimental infection of stallions with the KY84 strain of
EAV. These results agree with the findings of Neu et al. (1991) that deterioration in
semen quality following experimental EAV inoculation of stallions appears to be
temporary and that the duration of reduced semen quality corresponded approximately
with the duration of spermatogenesis in the horse (Brito, 2007).
Following inoculation with EAV KY84, all stallions shed virus in the semen
starting from 3 dpi until at least 107 dpi. Thus, presence of virus in semen was constant
throughout the experimental observation period. High body temperature and/or scrotal
edema caused by infection of the stallions with EAV KY84, were not a constant though,
and were observed sometime between 1-15 dpi during the acute phase of the disease.
Following 5-14 days of injury exposure (fever and/or scrotal edema), deleterious effects
on spermatogenesis were noticed. Statistical data analysis demonstrated strong evidence
that the edema and fever exerted independent deleterious effects on the quality of the
semen of all stallions evaluated, but virus seemed to exert little to no direct effect, as
virus concentrations remained high long after semen quality returned to baseline.
However, it is not possible to entirely rule out the direct effect of the virus infection on
semen quality given that, in a previous study, the KY84 strain of EAV was isolated from
the testis of stallions killed up to 20 dpi (Neu and Timoney, 1988). Nonetheless, it is
unlikely that virus, rather than the combined effect of fever and scrotal and preputial
edema, was responsible for the detrimental effect seen in semen quality, since
microscopic lesions observed in the reproductive tract of stallions during the acute phase
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of KY84 EAV infection were a result of viral replication and lysis of endothelial cells
and changes in germ cells were never reported (Neu, 1988).

In contrast,

histopathological changes in germ cells of testis exposed to heat were detect in different
species (Setchell, 1998).
It is well known that testicular temperature, 3 to 50C cooler than the body, is
required in most mammals in order for normal spermatogenesis to occur (Setchell, 1998;
Brito, 2007; Hansen, 2009). When testicular temperature is elevated due to conditions
such as fever, testicular trauma, inflammation, and edema, the thermoregulatory
mechanism necessary to cool the testis and allow for normal spermatogenesis is disrupted
(Johnson et al., 1997). In these conditions, metabolism and oxygen demand increase at a
greater rate than blood flow from the testicular artery to the testes, and testicular hypoxia
occurs with consequent detrimental effects on sperm production and quality (Setchell,
1998; Brito, 2007).

Previous studies assessing the effects of increased testicular

temperature in different species such as, mice (Pérez-Crespo et al., 2008), rams (Rasooli
et al., 2010), boars (Wettemann et al., 1979), bulls (Karabinus et al., 1997) and stallions
(Freidman et al., 1991; Love and Kenney, 1999) have shown that transient, as well as,
chronic exposure of the testis to elevated temperatures can disrupt spermatogenesis.
In this study, with the exception of one stallion (L141) that showed a drop only in
the number of MNS, semen of the other 6 stallions experimentally infected with EAV
showed a significant decrease in all parameters evaluated for semen quality (TMOT and
PMOT; TNS; LS; MNS; VCL) between 11-76 dpi. Stallion L141 had fever but not
edema during the acute phase of the disease. Perhaps, the fever in this animal was not
sufficient to elevate the intrascrotal temperature to a degree needed to interfere with
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motility, TNS, LS and VCL, but it was sufficient to decrease the percentage of MNS.
Neu et al. (1991) observed a similar outcome in a group of stallions experimentally
infected with EAV, which experienced a decrease in the percentage of MNS but not in
motility, and suggested that “mechanisms important in the formation or maintenance of
normal sperm structure may be the most sensitive to increased temperature”.
Statistical analysis predicted that semen quality of stallions inoculated with EAV
KY84 return to baseline values at around 76 dpi. This contrasts with the results obtained
by Neu et al. (Neu and Timoney, 1988) in which semen quality improved to
preinoculation values around 16 weeks post infection with EAV KY84 (112 dpi).
Perhaps, in that study, the effects of body temperature and scrotal edema more
dramatically affected spermatogonia, and thus, recovery of preinoculation semen
characteristics took longer to occur. Spermatogenesis in stallions is 57 days (Brito, 2007)
and is followed by the epididymal transit of spermatozoa, a process that lasts 8-11 days
(Swierstra et al., 1975). Therefore, spermatozoa evaluated anytime between 11 and 76
dpi were at different stages of development at the time of injury exposure (1-15 dpi). So,
it is possible to conclude that various stages of developing spermatozoa (spermatogonia,
primary spermatocytes, secondary spermatocytes, spermatids and mature sperm cells)
were sensitive to the effects of high body temperature and scrotal edema observed during
the acute phase of EAV infection. However, most of the morphological defects were
observed at around 41 dpi (nadir).

Taking into consideration the length of

spermatogenesis, the lifespans of primary (19 days) and secondary spermatocytes (0.7
days), spermatids with round nuclei (8.7 days) and elongated spermatids (10.1 days), as
well as knowing that epidydimal transit is approximately 9 days (Swierstra et al., 1974),
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the appearance of morphological abnormal cells mostly at 41 dpi, suggests that the cells
more dramatically affected at the time of testicular injuries were primary and secondary
spermatocytes. These results are similar to the results found by Freidman et al. (1991) in
which primary and secondary spermatocytes were the germ cells mostly affected
following 24 and 48h insulation of stallions’ testis.
In the assessment of morphological abnormalities, spermatozoa were assigned
only to one morphological category and the most proximal defect was prioritized over the
distal defects. The defects seen in spermatozoa were varied and all were increased
following experimental inoculation of the stallions with EAV KY84, with the exception
of the percentage of distal droplets that was decreased. The spermatozoa with distal
droplets decreased significantly between 23-58 dpi and this decrease did not mean
necessarily that their incidence had dropped, but rather, another abnormality had
increased. The period in which distal droplet abnormalities were significantly decreased
coincided with the period of most dramatic decrease (23-58 dpi) in the percentage of
MNS, when an increase in the multiple defects in the spermatozoa was seen.
Spermatozoa with detached heads had the most dramatic increase, with a 11-fold increase
occurring at 41 dpi, compared to baseline, followed by head abnormalities with a 4-fold
increase at 51 dpi. Detached heads and head defects are among those abnormalities that
appear to have a deleterious effect on fertility, and, even though, proximal droplets were
also observed on a high frequency after experimental infection of the stallions with EAV
KY84, the droplets seem to have a minor effect on fertility (Love et al., 2000).
It is important to mention that the values for onset of semen quality parameters as
well as for semen quality recovery are an oversimplification of interaction between the
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virus and host factors that occur during in vivo infection. Drop in semen quality was
gradual over time and it occurred at different times for different stallions as well as a
return to baseline values. As can be conclude from the graphics, there is an individual
variation in semen quality parameters among stallions following experimental inoculation
with the KY84 strain of EAV. Some stallions, for example, never experienced edema;
however, a mean exposure to edema was calculated (Fig 3.5.2.) and considered to occur
from 4-15 dpi.
In conclusion, fever and scrotal edema are the most likely cause of deterioration
of semen quality following experimental infection of stallions with the KY84 stain of
EVA. However, the direct effects of the virus on semen quality, even though unlikely,
cannot be excluded. The spermatozoa deterioration observed following experimental
inoculation of stallions with EAV KY84 were of enough magnitude to cause temporary
infertility of the stallions. In addition to the risk of acutely EAV infected stallions
becoming long-term carriers and shedding virus for years in semen, the deterioration in
semen quality of acutely EAV infected stallions can cause great economic loss associate
with the temporary removal of these animals from the breeding activities for as long as 3
to 4 months, until semen quality return to normal.
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CHAPTER FOUR
Summary of thesis

EAV is the causative agent of equine viral arteritis (EVA) and is distributed in
many equine populations throughout the world (Doll et al., 1957b; McCollum and
Bryans, 1973; Timoney and McCollum, 1993a). While most EAV infections are
asymptomatic or subclinical, some infected horses exhibit clinical manifestations
characteristic of EVA such as influenza-like illness in adult horses, abortion in pregnant
mares, pneumonia and/or enteritis in young foals, and persistent infection in stallions
(Doll, Bryans, and Knappenberger, 1957; Timoney, McCollum, Roberts, et al., 1986;
McCollum et al., 1999).
Over the years, the importation of carrier stallions and virus infective semen into
the U.S.A. has been responsible for the introduction of new strains of EAV and the
occurrence of new outbreaks of EVA. Experience over the past 20 plus years would
indicate that EAV infection is of increasing economic significance to the $102
billion/annum horse industry in the USA. Economic losses attributable to EAV infection
mainly include abortion, illness and death in young foals, the carrier state in stallions, and
restricted export markets for carrier stallions as well as virus infective semen or embryos
(Owens, 2005).
The establishment of persistent infection in the reproductive tract of the infected
stallions is a unique feature of EAV infection. Following EAV infection, a variable
proportion (30-60%) of stallions can become persistently infected and continuously shed
the virus in their semen for varying time periods, from weeks to years (Timoney,
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McCollum, Roberts, et al., 1986; Timoney, McCollum, and Roberts, 1986; Timoney et
al., 1987; Neu and Timoney, 1988). In 2006, a multistate occurrence of EVA was
confirmed in Quarter Horses for the first time, resulting primarily from the shipment of
EAV infective semen and the interstate movement of donor or embryo recipient mares.
During this 2006-2007 multistate EVA event, the disease also spread and affected other
horse breeds such as, Thoroughbreds, Warmbloods, Arabians, American Saddlebreds,
Paint Andalusian and led to the establishment of the carrier state in a significant number
of stallions (Timoney et al., 2008; Zhang et al., 2010).
Although multiple factors may contribute to the development of the carrier state,
host genetic variation is assumed to explain the individual differences in the occurrence
of the carrier state and virus clearance, because such variations exist even after exposure
of stallions to the same virus strain and dose. The profound differences in the breedspecific seroprevalence of EAV infections also might reflect inherent genetic differences
that confer resistance or susceptibility to infection (McCollum and Bryans, 1973).
Understanding of the nature of the interaction between the virus and the host is critical
for understanding the mechanism of virus persistence.
Recently, it has been demonstrated, with the use of flow cytometry, that the CD3+
T lymphocyte subpopulation of individual horses varied in their susceptibility to in vitro
VBS EAV infection (Go et al., 2010). In a parallel retrospective study our lab showed
that there is a correlation between the stallion carrier state of natural infected stallions and
the in vitro CD3+ T cell susceptible phenotype (Go et al., 2012). The data presented in the
second chapter of this thesis strongly suggests that stallions that have the CD3+ T cell
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phenotype seem to be at a higher risk of becoming persistently infected with EAV
following inoculation with the KY84 strain of EAV.
Furthermore, we investigated the effect of virus on semen quality of acutely and
persistently infected stallions. In the third chapter of this thesis it was demonstrated that
semen parameters are negatively affected following experimental infection of stallions
with the KY84 strain of EAV. High body temperature as well scrotal edema observed
during acute phase of infection exerted deleterious effects on all the semen quality
parameters. However high titers of virus in semen during acute or persistent infection of
the stallions seemed to have little or no effect on semen quality. The spermatozoa
deterioration observed following experimental inoculation of stallions with EAV KY84
were of enough magnitude to cause temporary infertility of the stallions. Thus, in
addition to the risk of acutely EAV infected stallions to become long-term carriers and
shed virus for years or entire life in semen, the deterioration in semen quality of acutely
EAV infected stallions can cause great economical loss associate with the temporary
removal of these animals from the breeding activities for as long as 3 to 4 months, until
semen quality return to normal.
The data presented in this dissertation suggest new directions for future EAV
research to enhance our understanding of the carrier state, as well as susceptibility to the
disease.
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